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ABSTRACT 
Medication adherence has been shown to be influenced by demographics, health status 
and socio-economic status of the patient. Thus, adherence-based measures of pharmacy quality 
may be influenced by patient-related risk factors outside of the healthcare provider’s control.  
This study examines the performance of a classical logistic regression model containing 
only patient characteristics and a random-effect model including patient characteristics and a 
pharmacy-specific effect in predicting medication adherence. These models were used to 
compute three different risk-adjusted scores on adherence-based pharmacy quality indicators: 
based on the classical logistic regression model (Method 1), the random effects model (Method 
2) and the shrinkage estimators of the random-effects model (Method 3). Finally, we compared 
the classification as low, medium or high quality pharmacies based on unadjusted and adjusted 
scores.  
This retrospective cohort study used the 2007 Mississippi Medicare administrative claims 
dataset. Patient medication adherence was measured using the proportion of days covered (PDC) 
measure for seven therapeutic classes of medications. Pharmacy Quality scores on adherence-
based measures were computed for all pharmacies serving Medicare beneficiaries in the state. 
The logistic regression model and the random-effect model displayed good predictive 
ability (c-statistic>0.7) for all therapeutic classes. The residual intra class correlation coefficient 
ranged from 0.008 to 0.012 indicating that although pharmacy level factors may have a 
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significant impact, they may not be as important as patient level factors in determining 
adherence. Higher levels of agreement was observed between pharmacy classification based on 
unadjusted scores and risk-adjusted scores obtained from Methods 1 and 2 (0.5<κ<0.74) with the 
percentage change in classification ranging from 16.3%-28.4%. Scores based on Method 3 
produced fewer outliers and showed minimal agreement with unadjusted scores (0.19<κ<0.35). 
When compared to risk-adjusted scores, unadjusted scores classified 8-12% of the low 
performing pharmacies as high performing and classified 20-30% of the pharmacies in the top 
20% as low performers.  
Risk-adjusted scores produced more robust indicators of pharmacy quality than 
unadjusted scores. Not adequately addressing the effects of patient case-mix while measuring 
quality could have severe implications if these measures are used for pay for performance 
programs or generating quality report cards. 
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CHAPTER I 
INTRODUCTION 
In their landmark study, Johnson and Bootman
1
 estimated that nearly 5 million hospital 
admissions and more than 100,000 deaths each year could be attributed to medication misuse. A 
newer study estimated that $45 billion could be saved annually if medications are used 
appropriately.
2
 Pharmacies and pharmacists play an important role in the healthcare system, 
improving health outcomes through better pharmaceutical care, disease management and 
medication therapy management, thereby preventing medication misuse.
3
 Yet, little information 
is available to evaluate the impact of these services. In November 2006, the Pharmacy Quality 
Alliance (PQA) contracted the National Committee for Quality Assurance (NCQA) to come up 
with pharmacy performance measures in 37 concept areas identified by the PQA.
4
 In 
collaboration with the Advanced Pharmacy Concepts (APC), the NCQA developed detailed 
specifications for 22 measures in the area of medication adherence and persistence, efficiency, 
safety, diabetes, cardiovascular and respiratory care. PQA has promoted the use of these 
standardized measures for the evaluation of pharmacy service quality at various levels within the 
healthcare system. 
However, it must be noted that these measures may be influenced by demographics, 
health status and socio-economic status of the patient population, which are factors outside of
2 
   
payers’ or healthcare providers’ control. For example, the researchers at RAND Health 
Corporation conducted a systematic review of the barriers to medication adherence and 
concluded that apart from costs and provider-related factors, patient characteristics such as 
diagnosis of depression and regimen complexity are among the most important barriers to 
medication adherence.
5
 They also found evidence that the number of prescribed medications may 
be related to adherence but not always in a specific direction.
6
 This study and numerous other 
studies of the predictors of medication adherence suggest a need to risk-adjust for patient 
characteristics while computing pharmacy quality scores that will be used to compare different 
payers or providers on adherence-related indicators.
6-15
 Failure to do so may result in 
comparisons that do not accurately reflect the effect of the individual providers and potential 
unfair rewards or penalties in pay-for-performance programs or other incentive/disincentive 
arrangements.  
The objectives of the current study were: 
 To examine the predictive ability of patient characteristics in medication adherence 
 To compute risk-adjusted scores on adherence-related pharmacy performance indicators 
 To compare unadjusted and adjusted scores on adherence-related pharmacy performance 
indicators 
This study sought to answer the important questions: Are case-mix adjustments needed 
when computing Pharmacy Quality Indicator scores for individual pharmacies and if so, what are 
the best adjustments to use? 
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CHAPTER II 
LITERATURE REVIEW 
Measuring Pharmacy Quality 
As healthcare in the United States moves to a value-driven model, there is an increased 
emphasis being placed on the measurement of quality of the service provided. The purpose of 
quality measurement is to identify problems in a system and track the effect of changes on 
quality, thereby ensuring continuous quality improvement.
16
 Over the past two decades, 
accreditation standards for providers have been modified to include collection and reporting of 
performance data.
17
 The data on performance have been used extensively by payers in the 
reimbursement of hospitals and physicians, better known as pay-for-performance.
18
 As of 2005, 
nearly two-thirds of the physicians in large group and staff model health maintenance 
organizations and greater than 30% of family practice physicians reported that quality had a role 
in their compensation.
19
 Public reporting of performance data has further stimulated quality 
improvement. Reports comparing the quality of hospitals,
20
 nursing homes
21
 and other 
institutional providers have been made available on a public domain by the Centers for Medicare 
and Medicaid Services (CMS) and the Joint Commission. The National Center for Quality 
Assurance provides information on the quality of health plans and managed care organizations 
using its set of measures (Health Effectiveness Data and Information Set-HEDIS).
22
 Physician 
report cards are now available at the clinic level and the demand for these at the individual level 
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is growing.
23
 However, quality measurement of medication use systems has remained 
relatively unexplored.
17
  
In 2006, the Pharmacy Quality Alliance (PQA) was formed with the mission of 
improving the quality of medication use across healthcare settings through a collaborative 
process in which key stakeholders agree on a strategy for measuring and reporting performance 
information related to medications.
24
 PQA is a voluntary, membership-based collaborative 
comprising organizations from the pharmacy, patient, employer, and health insurance plan 
communities, as well as state and federal government.
24
 At its outset PQA sought to identify 
pharmacist performance indicators or measures relevant to patients enrolled in Medicare Part D 
drug plans which could be put into place using existing data.
24
 On finding little evidence about 
the extensive use of any quality measures in the ambulatory or community pharmacy setting, 
PQA convened a Quality Metrics Workgroup which identified a starter set of 37 measure 
concepts in the areas adherence and persistence, efficiency, safety, and diabetes, cardiovascular 
and respiratory care.
4
  
After a competitive bidding process involving organizations with expertise in measure 
development the contract was awarded to the National Committee for Quality Assurance 
(NCQA). NCQA collaborated with Advanced Pharmacy Concepts (APC) to achieve the tasks of 
evaluating the feasibility of creating measures in each concept area, developing detailed 
specifications for each measure, and conducting initial measure testing using drug claims data.
25
 
NCQA created a set of 22 feasible measures which were pilot tested by Pillittere-Dugan et al.
25
 
using prescription claims data. The authors examined the variation of different performance 
measures within four different health plans. The authors concluded that performance measures 
related to medication adherence may be feasible and scientifically sound as there was found to be 
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sufficient variation in these measures across different pharmacies within a health plan suggesting 
possible room for improvement for some pharmacies. The study also points out some limitations 
in the implementation of these measures. Most importantly, only few pharmacies were reliably 
evaluated as most pharmacies did not meet the eligibility criterion of serving at least 30 members 
for each measure. Thus, the quality measures may not apply to all the pharmacies in a health 
plan. Another important limitation is the assumption that the measures used were at the control 
of the pharmacist and not influenced by any patient characteristics.  
Quality Indicators and the Importance of Case-Mix Adjustment 
Failure to account for patient case mix may result in unfair and improper assessment of 
the healthcare provider. Studies examining hospital quality indicators such as mortality rates, 
rates of readmission, complication rates have shown that risk-adjusting for age, race, gender, 
disease severity and comorbidity burden yield different hospital ratings from unadjusted 
performance measures.
26
 This is indicative of the fact that hospitals with a patient mix of poor 
health status to begin with are expected to perform worse on such measures; case mix or risk 
adjustment provides us with ratings that are potentially corrected for the effect of these risk 
factors. Recently, a study found that accounting for patient characteristics and treatment 
opportunity affected hospital rankings based on process measures such as adherence to treatment 
guidelines, for acute myocardial infarction.
26
 At the individual physician-level, numerous studies 
have shown the need for risk-adjusting for patient demographic characteristics and comorbidity 
burden while comparing specialist referral rates.
27-29
 The Center for Healthcare Strategies 
(CHCS) showed the importance of risk-adjustment in the evaluation of health-plan performance 
in the care provided to patients with chronic diseases.
30
 This report assessed the performance of 
six managed care plans participating in the Maryland Medicaid program. The care provided to 
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enrollees with asthma, diabetes, HIV/AIDS and schizophrenia was analyzed using healthcare 
utilization rates for emergency room visits and inpatient admissions as the outcome performance 
measures. It was found that health status of the population was strongly related to these measures 
and adjusting for the health status improved the accuracy of the performance measures.  
Influence of Patient Characteristics on Medication Adherence 
Numerous studies have shown that patient characteristics influence medication 
adherence, indicating a need for case-mix adjustment of adherence-related pharmacy quality 
measures. A commonly employed conceptual framework in explaining adherence consists of 
patient-related factors, provider-related factors and health-system factors as the predictors of 
medication adherence. Patient-related factors can further be categorized as demographics, 
coexisting illness, medication characteristics and cognitive functioning, all of which may 
influence health beliefs thereby affecting medication compliance behavior.
5
 Factors such as 
depression, beliefs about medication and medication characteristics such as number of 
prescriptions and regimen complexity, have been extensively studied.
5
  
In a recently published systematic review of studies examining the barriers to medication 
adherence for the RAND Corporation, Gellad et al.
5
 reported that evidence about the effect of 
number of chronic conditions and number of medications on medication adherence is unclear. 
Some studies suggest a positive relationship while others suggest a negative or a lack of 
relationship. For example, Billups et al.,
6
 using computerized prescription records, found that 
increased age, higher number of chronic conditions, and higher number of concurrent drugs were 
positively correlated with drug therapy compliance. Similarly Siegel et al.
7
 reported a positive 
association between antihypertensive medication adherence and older age, number of 
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cardiovascular medications and total number of medications using veterans’ pharmacy claims 
database. Similar results were obtained by Shalansky and Levy
8
 who report lower adherence to 
chronic cardiovascular regimens in patients taking fewer medications and Eagle et al.
9
 who 
found that patients with myocardial infarction and hypertension were more likely to be adherent 
to beta-blocker therapy than patients with just one of those conditions. Other studies using 
patient surveys, computerized prescription records from national pharmacy chains and pharmacy 
claims data have also shown an increase in adherence rates with an increase in the number of 
comorbidities especially in those treated with cardiovascular drugs.
5
  
However, Chapman et al.
10
 using managed care prescription claims and medical service 
data, report that patients with higher disease burden (52.1%) and patients with any complex 
chronic condition (48.1%) were more likely to be non-adherent. These findings are similar to the 
findings of other studies like that by Sung et al.,
11
 who found that patients with comorbidities, 
patients with multiple doses of antihyperlipidemic medications are less likely to be compliant. 
The complexity of dosing regimen has been recognized as an important predictor of medication 
adherence. Systematic reviews by Saini and colleagues
12
 as well as Ingersoll and Cohen
13
 
concluded that dosing frequency and regimen complexity (defined as multiple medications, 
multiple doses, and specific time requirements) are associated with poorer adherence rates. Apart 
from clinical characteristics, adherence rates have also been found to vary with age, gender and 
race-ethnic grouping.
5, 14-15
 Thus, in order to obtain an accurate assessment of pharmacy quality, 
the effects of patient characteristics must be adjusted for while computing pharmacy quality 
scores. 
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Risk-Adjustment Models 
Risk assessment models such as the Ambulatory Clinical Groups (ACG) system, 
Hierarchical Coexisting Conditions (HCCs) system and the Chronic and Disability Payment 
System (CDPS) have been widely used in risk-adjustment of capitated health plan payments and 
provider performance ratings.
31
 These diagnosis-based instruments provide a risk assessment 
based on the population health status and demographic profile. Diagnosis information based on 
International Classification of Disease, 9
th
 Revision, Clinical Modification (ICD-9-CM), codes 
available on automated information systems or from claims data is used.
31
 However, a few 
drawbacks of these diagnosis-based measures are worth mentioning. They are susceptible to 
coding-related issues, and may not reflect medication characteristics. Further, diagnosis 
information may not be available to pharmacies or other agencies tasked with the measurement 
of pharmacy performance using pharmacy data.  
Thus, a prescription-based risk-assessment model like the Rx-Risk system which aims to 
produce a risk assessment which reflects the comorbidity burden, medication characteristics such 
as the number of medications and the complexity of the medication regimen, would be ideal for 
the purpose of this study. The Rx-Risk system is a revised and expanded version of the Chronic 
Disease Score (CDS), a risk assessment instrument based on automated pharmacy data 
developed at Group Health Cooperation (GHC) of Puget Sound.
31
 The risk assessment produced 
is based on an individual’s age, sex and chronic condition profile measured by pharmacy 
dispenses linked to chronic conditions rather than diagnosis codes. Each drug dispensed is 
associated with a particular Rx-Risk category representing a chronic condition. A single 
dispensing of a drug is enough to be classified into an associated category. This helps to assure 
that adherent patients are not classified into more disease categories than non-adherent patients, 
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which would happen if multiple doses of a drug were required for classification into an 
associated chronic condition category. The Rx-Risk was designed to overcome some of the 
barriers of the earlier CDS in forecasting costs. Some categories in the CDS had to be modified 
to be used as a financial model for capitation adjustment. Further, the CDS was also developed 
and estimated within the GHC system, which meant that risk weights may reflect practice pattern 
and drug-use bias present in GHC and thereby limit its applicability. The Rx-Risk model was 
estimated and validated using data from approximately 1.5 million people sample of three large 
HMOs: GHC, HealthPartners of Minnesota and the Northeast Ohio and Rocky Mountain regions 
of Kaiser Permanente. The Rx-Risk system has been shown to perform at par with ACG and 
better than the Charlson comorbidity index (CCI) and the Elixhauser Index (EI) in the 
forecasting future healthcare costs
31
. More recently, the Rx-Risk instrument was found to have a 
better predictive ability compared to the CCI, the EI and the Health-related Quality of Life 
comorbidity index (HRQL-CI) in the prediction of adherence to treatment by physicians.
32
   
More importantly, this study also found that the risk assessment based on the Rx-Risk system 
was found to be a predictor of medication adherence in diabetic patients, whereas diagnosis-
based comorbidity indices, like the CCI and the EI, performed poorly in the prediction of 
adherence.
32
  
In this study, risk-adjusted scores on pharmacy performance measures were computed 
using patient demographic information and a chronic condition profile as measured by the Rx-
Risk instrument to adjust for patient characteristics. Pharmacy rankings based on unadjusted and 
risk-adjusted scores on adherence-related pharmacy performance measures were compared. 
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CHAPTER III 
METHODOLOGY 
Study Design and Data Sources 
A retrospective study was conducted using the 2007 Mississippi Medicare administrative 
claims datasets to compute and compare adjusted and unadjusted Pharmacy Quality scores on 
adherence-based Proportion of Days Covered (PDC) measures for pharmacies serving Medicare 
beneficiaries in the state.  
Medicare 
Medicare is a federally-funded, public health insurance program for patients 65 years of 
age or older, or those who meet special criteria, in the United States of America. The 
components of Medicare include hospital insurance (Part A), supplemental medical insurance 
(Part B), Medicare Advantage Plans (Part C) and prescription drug coverage (Part D).  Medicare 
data are made available in the form of Research Identifiable Files which contain person-specific 
data on providers, beneficiaries and recipients including individual identifiers such as age, date 
of birth, race, sex, residence information. The de-identified form of these files, with an encrypted 
ID to link all records for patients on different files, was used. Use of these data files was covered 
by a Data Use Agreement with CMS. The following files were used in this study: 
 Beneficiary Summary File: This file contains demographic and enrollment information 
for each Medicare beneficiary 
11 
   
 The Outpatient (submitted by institutional outpatient providers) and the Carrier 
(submitted by non-institutional outpatient providers) Standard Analytical Files or claim 
files which contain the final action claims data submitted by providers for 
reimbursement to CMS. 
 The MedPAR File which contains inpatient hospital and skilled nursing facility (SNF) 
final action stay records. Each record on this file represents a hospital or a skilled 
nursing facility stay. 
  Part D Drug Event (PDE) File: This file contains a summary record of each filled 
prescription by a beneficiary under Medicare Part D. 
This study used the Beneficiary Summary file to retrieve demographic and eligibility 
information on patients. The claims files and MedPAR files helped identify patients who met 
inclusion criteria for the computation of the adherence based performance measures. Further, the 
RX and PDE files were used to compute these measures at a patient and pharmacy-level. The RX 
and PDE files were also used to measure a patient’s RxRisk score based on the prescribed 
medications during the study period. Approval from the Institutional Review Board of the 
University of Mississippi was obtained under the exempt category.  
Study Variables 
Demographic Variables 
Information on patient demographics was obtained from the Beneficiary Summary 
(beneficiary_summary) file of the Medicare data. Specifically the variables listed in table 
BENE_AGE_AT_END_REF_YR, BENE_SEX_IDENT_CD, BENE_RACE_CD were used to 
obtain information on patient age, sex and race respectively.  
12 
   
Additionally, information on the Low-income subsidy status of Medicare individuals was 
obtained from the Beneficiary_summary file of the Medicare data. In the Medicare Part D 
program, enrollees are eligible for cost-sharing assistance programs based on income levels and 
other criteria. Based on income levels, enrollees may receive drug benefits without any premium 
or co-pay, or may be required to pay a premium but no co-pay, or may be required to pay both a 
premium and a co-pay. The variable COST_GRP from the beneficiary_summary file was used to 
determine low-income subsidy status. 
Rx-Risk System 
The Rx-Risk system or a chronic disease score uses patients’ prescription claims data to 
quantify their co-morbidity burden. The Rx-Risk model developed by Fishman et al. identifies 
29 chronic disease categories (see Appendix A) and specifies all the classes of medications that 
belong to each category. Patients were assigned to a chronic disease category if they filled a 
prescription for any medication in that chronic disease category during the measurement period. 
Patients could have been assigned to multiple categories based on their prescription fills in the 
measurement period.   
For each prescription record, the medication class was identified using the associated 
National Drug code. The Product Service ID (PROD_SRVC_ID) field of the Medicare 
prescription drug event file was used to obtain the National Drug Code of the prescribed 
medication. 
Pharmacy Quality Indicator Score 
NCQA developed a set of performance measures based on the conceptual foundations 
provided by Pharmacy Quality Alliance that could be widely implemented in the reporting and 
13 
   
assessment of pharmacy quality. This study evaluated pharmacy performance on a subset of 
these measures in the area of medication adherence. Specifically, pharmacies were evaluated on 
the proportion of days covered (PDC) measure. The quantification of pharmacy performance was 
based on the technical specifications and implementation guidelines provided by NCQA.  
Proportion of Days Covered (PDC) Measure   
As defined by the NCQA, PDC measures assess the proportion of patients “covered” by a 
drug or another drug in the same therapeutic class during the measurement period. At the patient-
level PDC is calculated as the proportion of days in the measurement period covered by 
prescription claims for a given medication or any other medication in that therapeutic category. 
A PDC threshold of 0.8 (80%), was used to classify patients as “covered”. Pharmacy 
performance on the PDC measure was assessed following the steps below: 
 Step 1: Each patient’s measurement period was identified as the period beginning on the 
date of the index prescription (first prescription in the calendar year) and ending on the 
date of disenrollment, death, the last day of the year or the last day covered by the final 
prescription fill in the year if it was before the last date of the year 
 Step 2: In the measurement period the number of days for which the patient is covered 
by prescription claim for a drug or another medication in the same class was counted. If 
the dates covered by different prescription claims for the same drug overlapped, then an 
adjustment was made to start counting the days covered by the subsequent prescription 
claim after the last date covered by the previous prescription. 
 Step 3: The number obtained in step 2 was divided by that in step 1 to get the PDC for 
each patient. 
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 Step 4: Patients were attributed to a particular pharmacy if they received at least 75% of 
their prescription fills at that pharmacy  
 Step 5: Within each pharmacy, the number of patients who met the PDC threshold of 0.8 
(measure numerator) was divided by the number of patients eligible for the PDC 
measure (measure denominator) to arrive at the final measure of Pharmacy performance. 
A separate proportion was calculated for each of the following six classes of medications: 
 Beta-blocker (BB)  
 Angiotensin-converting enzyme (ACE) inhibitor or Angiotensin-receptor blocker (ARB)  
 Calcium Channel Blocker (CCB)  
 Biguanide  
 Sulfonylurea  
 Thiazolidinedione  
 Statin  
To have been eligible for measure computation, a patient must have filled at least two 
prescriptions for a medication or a combination medication in that therapeutic class (see 
Appendix B for list of medications) on two unique dates of service in the measurement year. The 
lists of medications in each class as specified in the NCQA guidelines is given below.  
Additionally, the NCQA lists the following eligibility criteria for including a patient in 
the denominator of the pharmacy performance measure: 
 Age – Patient must be 18 years or older as of the last day of the measurement year. 
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 Enrollment – The patient must be enrolled to receive Medicaid/Medicare benefits for the 
measurement year and must have no more than one gap of up to 45 days during the 
enrollment year. For Medicaid beneficiaries the member should not have a gap of more 
than one month in the year when enrollment status is measured on a monthly basis.  
 Pharmacy benefits - The patient must be enrolled to receive pharmacy benefits during 
the measurement year. 
Finally, the NCQA guidelines specify that patients who meet the above eligibility criteria 
but had a non-acute stay in the measurement year be excluded from the denominator of the 
measure. To identify patients receiving non-acute care the claims based exclusions table (Table 
1) below was used. 
Table 1 - Claims based exclusions table 
Description HCPCS UB Revenue UB Type of 
Bill 
DRG POS 
Hospice  0115, 0125, 
0135, 0145, 
0155, 0650, 
0656, 0658, 
0659 
81x, 82x  34 
SNF  019x 21x, 22x, 28x  31, 32 
Hospital transitional 
care, swing bed or 
rehabilitation 
  18x   
Rehabilitation  0118, 0128, 
0138, 0148, 
0158 
 462  
Respite  0655    
Intermediate care 
facility 
    54 
Residential substance 
abuse treatment facility 
 1002   55 
Psychiatric residential 
treatment center 
T2048, 
H0017-H0019 
1001   56 
Comprehensive 
inpatient rehabilitation 
facility 
    61 
Other nonacute care facilities that do not use the UB Revenue or Type of Bill codes for billing 
(e.g., ICF, SNF) 
  
16 
   
If event codes are not available patients were excluded if they met one of the following 
conditions: 
 Long-term care indicator field was populated on claims  
 The NCPD or NABP code on the claim identified a long-term care specific pharmacy 
 PBM pharmacy indicator type indicated a long-term care specific pharmacy 
 Medicare claims with a zero co-pay were present  
Scores on pharmacy performance measures were only calculated for pharmacies with at 
least 30 patients in the measure denominator.  
Pharmacy Attribution    
It is imperative that patients are accurately attributed to pharmacies. Inaccuracy may lead 
to some pharmacies being unfairly penalized for the quality of services received by the patient 
when the pharmacy has not had enough opportunities to impact it. Alternatively, pharmacies may 
unfairly benefit from the higher quality of prior services received by the patient elsewhere. 
Taking this into consideration, the NCQA developed specific rules for pharmacy attribution 
which were followed in this study: 
 If patients qualifying for the denominator of a measure receive all of their prescriptions 
from one pharmacy they were attributed to that pharmacy. 
 If patients qualifying for the denominator of a measure receive their prescriptions for a 
medication within the identified drug class or drug classes, from multiple pharmacies, 
they were attributed to the pharmacy which filled at least 75% of their prescriptions for 
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the medications in the identified drug class or drug classes when data from multiple 
pharmacies are available.    
Statistical Analysis 
Unadjusted pharmacy quality indicator score 
As outlined above, the unadjusted measure of pharmacy performance or unadjusted 
pharmacy quality indicator score was calculated as the proportion of eligible patients within each 
of the pharmacies who met the PDC threshold of 0.8. A 95 % confidence interval for this 
measure was calculated using a normal approximation as: 
        √  (    )             (1) 
Where    is the unadjusted quality indicator score for pharmacy j, and    is the number of 
patients in pharmacy j. 
Objective 1: To examine the predictive ability of patient characteristics in medication adherence 
Method 1 
Medication adherence for patient i in pharmacy j was defined as a binary variable Yij 
which equaled ‘1’ for patients classified as being adherent (PDC>=0.8) and ‘0’ for patients 
classified as being non-adherent (PDC<0.8). A classical logistic regression model was estimated 
to predict the log odds of adherence (equation 1) for each patient in the sample. This included all 
patients meeting the enrollment criteria and found to be eligible for the denominator of the 
corresponding pharmacy performance measure. The predictor variables in this model included 
categorical variables for race, sex and low income subsidy status, continuous variables for age 
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and the average number of prescriptions per 30 days, and dichotomous variables indicating the 
presence of each RxRisk category.  
The logistic regression model was estimated as: 
  (
   
     
)                                 (2)   
where     is the probability of being adherent for patient i in pharmacy j,    are model 
parameters,      are values of individual predictor variables.  
The predictive ability of the model was examined using the c-statistic which is equal to the area 
under the receiver operating characteristic curve. The c-statistic provides a measure of the 
model’s ability to discriminate between adherent and non-adherent patients. The c-statistic 
ranges from 0.5 (no discrimination, might as well flip a coin) to 1.0 (perfect discrimination). 
Method 2 
Alternatively, a hierarchical logistic regression model with a random intercept was 
estimated on the same data as: 
  (
   
     
)                                 (3) 
where     is the probability of being adherent for patient i in pharmacy j,    are model 
parameters,      are values of individual predictor variables,    is the random intercept for 
pharmacy j. This model consists of the same predictor variables used in the classical logistic 
regression model but accounts for the nesting of patients within a pharmacy by including an 
intercept term that is different for each pharmacy. This intercept term is taken to be random and 
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is expressed as a linear combination of the average intercept   and a group dependent deviation 
given by the random variable   . The random variable    was assumed to follow a normal 
distribution with mean of zero and variance of   
  and independent of the patient-level residuals:  
                   (4) 
         
              (5) 
The pharmacy-specific intercepts provide a measure of the effect of the pharmacy on 
adherence controlling for all the patient-level variables in the model. The predictive ability of 
this model was also examined using the c-statistic. 
Additionally, the residual intraclass correlation coefficient was computed to provide a 
measure of variation between pharmacies. The residual intraclass correlation coefficient is a 
measure of the correlation between two individuals chosen at random from any random 
pharmacy. It translates to the proportion of the unexplained variation after controlling for the 
effect for the explanatory variables that can be attributed to variation at the pharmacy-level (or 
group membership). The patient-level residuals follow a logistic distribution which implies a 
fixed variance of     . The intraclass correlation coefficient for the random-intercept model was 
estimated as suggested by Snijders and Bosker
33
 as: 
  
  
 
  
      
             (6) 
Where   is the intraclass coefficient,   
  is the variance of the random part of the 
pharmacy specific intercepts,      is the variance of patient-level residuals. 
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Objective 2: To compute risk-adjusted scores of pharmacy performance on medication 
adherence-related measures  
Method 1 
The classical logistic regression model outlined above was used to estimate the predicted 
probability of adherence  ̂    for patient i in pharmacy j. For a given pharmacy the expected 
quality indicator score was calculated as the average of the individual predicted probabilities of 
patients within that pharmacy. 
    
 
  
 ∑  ̂   
  
               (7) 
Where     is the expected quality indicator score for pharmacy j,  ̂    is the predicted 
probability of adherence for patient i, and    is the number of patients at pharmacy j. 
The risk-adjusted performance measure for each pharmacy was calculated as the ratio of 
observed (or unadjusted) quality indicator score to the expected quality indicator score:       . 
The 95 % confidence intervals of        was calculated as suggested by Hosmer and 
Lemeshow,
34
 as: 
        
√∑  ̂   
  
   (   ̂   )
  
   
 
(8) 
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Method 2 
Alternatively, the hierarchical logistic regression model with a random intercept outlined 
above was used to estimate the predicted probability (assuming null effect of   ) of adherence 
 ̂    for patient i in pharmacy j. For a given pharmacy the expected quality indicator score was 
calculated as the average of the individual predicted probabilities of patients within that 
pharmacy. 
    
 
  
 ∑  ̂   
  
               (9) 
Where     is the expected quality indicator score for pharmacy j and  ̂    is the predicted 
probability of adherence for patient i based on Method 2 and    is the number of patients at 
pharmacy j. 
Once again, the risk-adjusted performance measure for each pharmacy was calculated as 
the ratio of observed (or unadjusted) quality indicator score to the expected quality indicator 
score:       . 
The upper and lower bounds of the confidence interval of the risk-adjusted measure 
       was calculated using the same formula described in equation 8.  
Method 3 
As mentioned earlier, the pharmacy specific intercepts provide a measure of the effect of 
the pharmacy after accounting for the patient-level explanatory variables. Specifically, the 
exponentiation of the random variable,         is equal to the ratio of the odds of adherence at 
pharmacy j to the odds of adherence at the average pharmacy controlling for patient 
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characteristics. This final method uses the exponentiation of the random variable    (or shrinkage 
estimator   ) as a risk-adjusted measure of pharmacy performance. The 95 % confidence interval 
of this risk-adjusted measure was calculated using the 95 % CI of   . 
Objective 3: To compare unadjusted and adjusted scores on adherence-related pharmacy 
performance measures.  
Based on their quality indicator scores pharmacies were classified as low-quality outliers, 
medium-quality pharmacies and high-quality outliers.  
The average unadjusted pharmacy quality indicator score on each PDC measure was 
calculated as the sum of quality indicator scores of all pharmacies divided by the total number of 
pharmacies. Pharmacies were classified as low-quality outliers if their unadjusted score was less 
than the average unadjusted score and their 95 % CI of their unadjusted score did not contain the 
average unadjusted score. Pharmacies were classified as high-quality outliers if their unadjusted 
score was higher than the average unadjusted score and their 95 % CI of their unadjusted score 
did not contain the average unadjusted score.
 
Pharmacies were classified as medium-quality if 
the 95 % CI of their unadjusted score contained the average unadjusted score.
35
  
Similarly, for all three risk adjustment methods which yield a ratio as the final measure of 
performance, pharmacies were classified as follows: Pharmacies were classified as low-quality 
outliers if their risk-adjusted score was less than 1 and their 95 % CI of their unadjusted score did 
not contain 1.
 
Pharmacies were classified as high-quality outliers if their risk-adjusted score was 
higher than 1 and their 95 % CI of their risk-adjusted score did not contain 1.
 
Pharmacies were 
classified as medium-quality if the 95 % CI of their risk-adjusted score contained 1.
35
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The agreement in pharmacy classification based on unadjusted and adjusted scores 
obtained from the three different methods detailed above was evaluated using Cohen’s Kappa (κ)  
coefficient.  
Further, agreement in the identification of high quality pharmacies, defined as the top 
20% of the distribution, using unadjusted and adjusted scores was also evaluated.   
All analyses were conducted using SAS, version 9.2 (SAS Institute, Inc., Cary, North 
Carolina). 
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CHAPTER IV 
RESULTS 
Beta Blockers 
At the patient-level, PDC measures for this class of medications were computed for 
53,975 Medicare patients who met eligibility criteria. These patients were attributed to a total of 
620 pharmacies in the state for which quality indicator scores were computed according to 
NCQA specifications. 
Table 2 shows the odds ratio estimates of patient characteristics used to predict adherence 
to beta blockers using a classical logistic regression model and a random-intercept model. The 
odds ratio estimates of all patient characteristics were similar in both models. Adherence was 
strongly associated with the average number of prescriptions per month. Patients with a greater 
number of average prescriptions per month had higher odds of being adherent to beta blockers. 
Presence of most medical conditions, as measured by the RxRisk measure, was associated with 
significantly lesser odds of being adherent to beta blockers. The c-statistic was 0.721 for the 
classical logistic regression model and 0.729 for the random intercept model which shows good 
discriminative ability for both models. 
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Table 2. Odds ratio estimates of baseline patient characteristics in risk adjustment models 
– Beta Blockers 
Baseline Characteristics 
Prevalence(%) 
or 
Classical Logistic 
Regression Model 
Random Intercept 
Model 
Mean ± SD Point 
Estimate 
P-Value 
Point 
Estimate 
P-Value 
RxRisk Category  
 Anxiety and 
tension  
12.47 0.678 <.0001 0.676 <.0001 
 Asthma  20.58 0.645 <.0001 0.647 <.0001 
 Bipolar disorder  0.25 1.043 0.8344 1.031 0.8792 
 Cardiac disease  12.19 0.534 <.0001 0.533 <.0001 
 Vascular disease  13.05 0.761 <.0001 0.757 <.0001 
 Cystic fibrosis  0.06 0.316 0.0029 0.322 0.0038 
 Depression  28.53 0.630 <.0001 0.629 <.0001 
 Diabetes  29.97 0.641 <.0001 0.638 <.0001 
 Epilepsy  14.87 0.644 <.0001 0.644 <.0001 
 ESRD  0.19 0.672 0.0886 0.665 0.0808 
 Gastric acid 
disorder  
34.55 0.681 <.0001 0.680 <.0001 
 Gout  7.62 0.764 <.0001 0.763 <.0001 
 AIDS  2.56 0.850 0.0090 0.846 0.0076 
 Hyperlipidemia  51.88 0.800 <.0001 0.797 <.0001 
 Inflammatory 
bowel disorder  
10.39 0.788 <.0001 0.789 <.0001 
 Liver disease  1.55 0.639 <.0001 0.635 <.0001 
 Malignancies  9.97 0.773 <.0001 0.774 <.0001 
 Parkinson’s  3.84 0.739 <.0001 0.731 <.0001 
 Psychotic illness  5.77 0.726 <.0001 0.725 <.0001 
 Renal disease  0.34 0.920 0.6289 0.916 0.6122 
 Rheumatoid 
arthritis  
14.55 1.074 0.1097 1.071 0.1265 
 Thyroid disorder  14.59 0.744 <.0001 0.741 <.0001 
 Transplant  0.28 0.907 0.6138 0.906 0.6124 
 Tuberculosis  0.31 0.705 0.0505 0.702 0.0479 
 Pain  44.47 0.661 <.0001 0.664 <.0001 
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Using the random-intercept model, the pharmacy-level variance component was 
estimated to be 0.03382 with a standard error of 0.005714. Testing the null hypothesis of no 
random effects and complete independence of all the observations using a likelihood ratio test 
based on residual pseudo likelihoods yielded a chi-square of 73.36 (p<0.0001), indicating non-
zero covariance parameters (or presence of random effect). The residual intraclass correlation 
coefficient (ρ) for the random intercept model was estimated to be 0.01017 which indicates that 
 Pain and 
inflammation  
23.15 0.867 <.0001 0.868 <.0001 
 Glaucoma  7.74 0.818 <.0001 0.817 <.0001 
Race 
 North American 
Native 
0.11 Reference Reference Reference Reference 
 Unknown race  0.03 0.613 0.0450 0.574 0.3917 
 White  65.74 2.887 <.0001 2.769 0.0008 
 Black  33.71 1.636 0.9285 1.578 0.1341 
 Other  0.18 2.593 0.0502 2.514 0.0165 
 Asian  0.18 2.253 0.1692 2.145 0.0466 
 Hispanic  0.06 1.997 0.5840 1.921 0.1843 
Sex 
 Female 64.47 Reference Reference Reference Reference 
 Male 35.53 0.893 <.0001 0.894 <.0001 
Age  71.07±11.54 1.010 <.0001 1.010 <.0001 
Cost share group
a 
 No Premium 
Subsidy 
47.47 Reference Reference Reference Reference 
 Subsidy group 1  3.13 1.234 0.0026 1.253 0.0129 
 Subsidy group 2 47.28 0.901 <.0001 0.908 <.0001 
 Subsidy group 3 2.11 0.972 0.4017 0.976 0.7351 
Prescriptions per month  5.58±3.11 1.454 <.0001 1.459 <.0001 
a
Subsidy Group 1 consisted of beneficiaries with 100% premium-subsidy and no copayment. Subsidy Group 2 
consisted of beneficiaries with 100% premium-subsidy and low copayment/high copayment and beneficiaries with a 
low income subsidy, a 100% premium-subsidy and high copayment. Subsidy Group 3 consisted of beneficiaries 
with low income subsidy, 15% copayment and 25%-100% premium-subsidy. 
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1.02% of the unexplained variation after controlling for patient-level variables could be 
attributed to variation between pharmacies.   
Table 3 shows the agreement between the unadjusted quality indicator scores and the 
risk-adjusted quality indicator scores. Low quality outliers are those pharmacies whose scores on 
the pharmacy quality indicator are significantly lower than the average quality score in this 
sample of pharmacies according to the 95% confidence interval of the measures. High quality 
outliers are those pharmacies whose pharmacy quality indicator scores are significantly higher 
than the average quality score in this sample of pharmacies according to the 95% confidence 
interval of the measures. Pharmacies of medium quality are those whose quality scores are not 
significantly different from the average quality score in the sample.  
Agreement between pharmacy classification based on unadjusted and risk-adjusted scores 
was similar when risk adjustment was done using a classical logistic regression model (κ=0.61) 
and when adjustment was based on a random intercept model (κ=0.59) and the least when risk 
adjustment was based on the shrinkage estimators of the random intercept model (κ=0.34).   
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Table 3. Agreement in identifying Pharmacy Quality Outliers: Comparison of unadjusted 
and risk-adjusted pharmacy quality indicator scores – Beta Blockers 
Outlier 
status based 
on 
unadjusted  
performance 
rating 
Outlier Status Based on Risk Adjustment 
Method 1
a
 Method 2
b
 Method 3
c
 
 Low Medium High Low Medium High Low Medium High 
Low  90 49 1 92 47 1 40 99 1 
Medium  27 283 28 33 277 28 2 332 4 
High  1 33 108 1 36 105 1 98 43 
Percentage 
change in 
classification 
(%)
d
  
23.7 22.5 21.2 26.7 23.1 21.6 6.97 37.2 10.4 
Overall κe  0.61 0.60 0.34 
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Percentage change was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the initial classification. 
e
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based 
on the risk adjustment method with higher values indicating greater agreement 
 
Table 4 shows a comparison of the three different risk adjustment methods used. 
Pharmacy classification based on risk-adjusted scores obtained using Method 1 and 2 showed 
nearly perfect agreement (κ=0.97). Classification based on Method 3 showed only moderate 
agreement with classification based on Method 1 (κ=0.43) and Method 2 (κ=0.42). Method 3 
also identified fewer high and low quality outliers compared to the other risk adjustment 
methods.  
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Table 4. Agreement in identifying Pharmacy Quality Outliers: Comparison of risk 
adjustment methods – Beta Blockers 
Outlier status 
Based on Risk 
Adjustment 
Method 
Outlier Status Based on Risk Adjustment Method 
Method 1
a
 Method 2
b
 
Method 2
b
   
Low Medium High 
Low  118 8 0 
Medium  0 357 3 
High  0 0 134 
Overall κd  0.97 
Method 3
c
     
Low Medium High Low Medium High 
Low  43 0 0 43 0 0 
Medium  75 365 89 83 360 86 
High  0 0 48 0 0 48 
Overall κd  0.43  0.42  
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based 
on the risk adjustment method with higher values indicating greater agreement 
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Calcium Channel Blockers 
At the patient-level, PDC measures for this class of medications were computed for 
50,577 Medicare patients who met eligibility criteria. These patients were attributed to a total of 
606 pharmacies in the state for which quality indicator scores were computed according to 
NCQA specifications. 
Table 5 shows the odds ratio estimates of patient characteristics used to predict adherence 
to calcium channel blockers using a classical logistic regression model and a random-intercept 
model. The odds ratio estimates of all patient characteristics were similar in both models. 
Adherence was strongly associated with the average number of prescriptions per month. Patients 
with a greater number of average prescriptions per month had higher odds of being adherent to 
calcium channel blockers. Presence of most medical conditions, as measured by the RxRisk 
measure, was associated with significantly lesser odds of being adherent to calcium channel 
blockers. The c-statistic was 0.728 for the classical logistic regression model and 0.734 for the 
random intercept model which shows good discriminative ability for both models. 
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Table 5. Odds ratio estimates of baseline patient characteristics in risk adjustment models – 
Calcium Channel Blockers 
Baseline Characteristics  
Prevalence(%) 
or 
Classical Logistic 
Regression Model 
Random Intercept 
Model 
Mean ± SD Point 
Estimate 
P-Value 
Point 
Estimate 
P-Value 
RxRisk Category  
 Anxiety and 
tension  
11.45 0.647 <.0001 0.646 <.0001 
 Asthma  20.62 0.687 <.0001 0.688 <.0001 
 Bipolar disorder  0.18 0.850 0.5077 0.844 0.4927 
 Cardiac disease  7.87 0.535 <.0001 0.535 <.0001 
 Vascular disease  9.89 0.766 <.0001 0.762 <.0001 
 Cystic fibrosis  0.09 0.789 0.5201 0.775 0.4908 
 Depression  25.22 0.661 <.0001 0.659 <.0001 
 Diabetes  30.87 0.653 <.0001 0.652 <.0001 
 Epilepsy  13.53 0.654 <.0001 0.653 <.0001 
 ESRD  0.26 0.611 0.0173 0.610 0.0172 
 Gastric acid 
disorder  
32.82 0.667 <.0001 0.664 <.0001 
 Gout  6.60 0.704 <.0001 0.702 <.0001 
 AIDS  2.24 0.984 0.8264 0.987 0.8641 
 Hyperlipidemia  44.15 0.752 <.0001 0.750 <.0001 
 Inflammatory 
bowel disorder  
10.60 0.747 <.0001 0.749 <.0001 
 Liver disease  1.74 0.734 0.0003 0.736 0.0003 
 Malignancies  9.88 0.742 <.0001 0.740 <.0001 
 Parkinson’s  3.23 0.667 <.0001 0.667 <.0001 
 Psychotic illness  5.73 0.685 <.0001 0.680 <.0001 
 Renal disease  0.31 0.587 0.0042 0.593 0.0052 
 Rheumatoid 
arthritis  
14.42 1.006 0.9024 1.003 0.9567 
 Thyroid disorder  13.18 0.775 <.0001 0.775 <.0001 
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Using the random-intercept model, the pharmacy-level variance component was 
estimated to be 0.02887 with a standard error of 0.005844. Testing the null hypothesis of no 
random effects and complete independence of all the observations using a likelihood ratio test 
based on residual pseudo likelihoods yielded a chi-square of 45.48 (p<0.0001), indicating non-
 Transplant  0.29 0.669 0.0425 0.670 0.0441 
 Tuberculosis  0.28 0.742 0.1279 0.738 0.1222 
 Pain  43.45 0.653 <.0001 0.655 <.0001 
 Pain and 
inflammation  
25.92 0.891 <.0001 0.890 <.0001 
 Glaucoma  10.28 0.899 0.0040 0.898 0.0036 
Race 
 North American 
Native 
0.19 Reference Reference Reference Reference 
 Unknown race  0.05 2.796 0.5424 2.557 0.0929 
 White  52.63 3.405 <.0001 3.218 <.0001 
 Black  46.76 2.145 0.9664 2.031 0.0075 
 Other  0.16 2.143 0.9808 2.051 0.0480 
 Asian  0.15 2.807 0.2994 2.601 0.0118 
 Hispanic  0.06 1.759 0.5697 1.691 0.2771 
Sex 
 Female 67.96 Reference Reference Reference Reference 
 Male 32.04 1.034 0.1736 1.034 0.1774 
Age  71.76±11.6 1.015 <.0001 1.015 <.0001 
Cost share group
a 
 No Premium 
Subsidy 
41.02 Reference Reference Reference Reference 
 Subsidy group 1  3.23 0.933 0.8906 0.965 0.6974 
 Subsidy group 2 53.71 0.857 0.0133 0.862 <.0001 
 Subsidy group 3 2.04 0.914 0.8571 0.915 0.2630 
Prescriptions per month  5.27±3.01 1.474 <.0001 1.477 <.0001 
a
Subsidy Group 1 consisted of beneficiaries with 100% premium-subsidy and no copayment. Subsidy Group 2 
consisted of beneficiaries with 100% premium-subsidy and low copayment/high copayment and beneficiaries with a 
low income subsidy, a 100% premium-subsidy and high copayment. Subsidy Group 3 consisted of beneficiaries with 
low income subsidy, 15% copayment and 25%-100% premium-subsidy. 
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zero covariance parameters (or presence of random effect). The residual intraclass correlation 
coefficient (ρ) for the random intercept model was estimated to be 0.0087 which indicates that 
0.87% of the unexplained variation after controlling for patient-level variables could be 
attributed to variation between pharmacies.   
Table 6 shows the agreement between the unadjusted quality indicator scores and the 
risk-adjusted quality indicator scores. Low quality outliers are those pharmacies whose scores on 
the pharmacy quality indicator are significantly lower than the average quality score in this 
sample of pharmacies according to the 95% confidence interval of the measures. High quality 
outliers are those pharmacies whose pharmacy quality indicator scores are significantly higher 
than the average quality score in this sample of pharmacies according to the 95% confidence 
interval of the measures. Pharmacies of medium quality are those whose quality scores are not 
significantly different from the average quality score in the sample. 
Agreement between pharmacy classification based on unadjusted and risk-adjusted scores 
was similar when risk adjustment was done using a classical logistic regression model (κ=0.51) 
and a random intercept model (κ=0.52) and the least when risk adjustment was based on the 
shrinkage estimators of the random intercept model (κ=0.23).   
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Table 6. Agreement in identifying Pharmacy Quality Outliers: Comparison of unadjusted 
and risk-adjusted pharmacy quality indicator scores – Calcium Channel Blockers 
Outlier 
status based 
on 
unadjusted  
performance 
rating 
Outlier Status Based on Risk Adjustment 
Method 1
a
 Method 2
b
 Method 3
c
 
 Low Medium High Low Medium High Low Medium High 
Low  79 50 0 80 49 0 25 104 0 
Medium  39 267 31 39 268 30 1 329 7 
High  2 49 89 2 49 89 1 111 28 
Percentage 
change in 
classification 
(%)
d
  
34.2 27.0 25.8 33.9 26.7 25.2 7.4 39.5 20 
Overall κe  0.51 0.52 0.23 
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Percentage change was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the initial classification. 
e
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based 
on the risk adjustment method with higher values indicating greater agreement 
 
Table 16 shows a comparison of the three different risk adjustment methods used. 
Pharmacy classification based on risk-adjusted scores obtained using Method 1 and 2 showed 
nearly perfect agreement (κ=0.97). Classification based on Method 3 showed less than moderate 
agreement with classification based on Method 1 (κ=0.33) and Method 2 (κ=0.33). Method 3 
also identified fewer high and low quality outliers compared to the other risk adjustment 
methods.  
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Table 7. Agreement in identifying Pharmacy Quality Outliers: Comparison of risk 
adjustment methods – Calcium Channel Blockers 
Outlier status 
Based on Risk 
Adjustment 
Method 
Outlier Status Based on Risk Adjustment Method 
Method 1
a
 Method 2
b
 
Method 2
b
   
Low Medium High 
Low  120 1 0 
Medium  0 365 1 
High  0 0 119 
Overall κd  0.99 
Method 3
c
     
Low Medium High Low Medium High 
Low  27 0 0 27 0 0 
Medium  93 366 85 94 366 84 
High  0 0 35 0 0 35 
Overall κd  0.33  0.33  
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based 
on the risk adjustment method with higher values indicating greater agreement 
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Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker (ACEI/ARB) 
At the patient-level, PDC measures for this class of medications were computed for 
87,220 Medicare patients who met eligibility criteria. These patients were attributed to a total of 
682 pharmacies in the state for which quality indicator scores were computed according to 
NCQA specifications. 
Table 8 shows the odds ratio estimates of patient characteristics used to predict adherence 
to ACEI/ARBs using a classical logistic regression model and a random-intercept model. The 
odds ratio estimates of all patient characteristics were similar in both models. Adherence was 
strongly associated with the average number of prescriptions per month. Patients with a greater 
number of average prescriptions per month had higher odds of being adherent to ACEI/ARBs. 
Presence of most medical conditions, as measured by the RxRisk measure, was associated with 
significantly lesser odds of being adherent to ACEI/ARBs. However, patients with Rheumatoid 
Arthritis had higher odds of being adherent compared to those without the condition. The c-
statistic was 0.715 for the classical logistic regression model and 0.723 for the random intercept 
model which shows good discriminative ability for both models. 
 
 
 
 
. 
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Table 8. Odds ratio estimates of baseline patient characteristics in risk adjustment models – 
ACEI/ARB 
Baseline Characteristics 
Prevalence(%) 
or 
Classical Logistic 
Regression Model 
Random Intercept 
Model 
Mean ± SD Point 
Estimate 
P-Value 
Point 
Estimate 
P-Value 
RxRisk Category  
 Anxiety and 
tension  
11.45 0.699 <.0001 0.697 <.0001 
 Asthma  20.43 0.629 <.0001 0.631 <.0001 
 Bipolar disorder  0.21 1.019 0.9152 1.002 0.9919 
 Cardiac disease  8.66 0.534 <.0001 0.532 <.0001 
 Vascular disease  9.69 0.715 <.0001 0.712 <.0001 
 Cystic fibrosis  0.06 0.273 <.0001 0.274 <.0001 
 Depression  26.28 0.620 <.0001 0.617 <.0001 
 Diabetes  35.48 0.718 <.0001 0.714 <.0001 
 Epilepsy  14.21 0.667 <.0001 0.667 <.0001 
 ESRD  0.17 0.564 0.0029 0.557 0.0025 
 Gastric acid 
disorder  
32.05 0.683 <.0001 0.679 <.0001 
 Gout  6.48 0.706 <.0001 0.702 <.0001 
 AIDS  2.35 0.944 0.2728 0.941 0.2462 
 Hyperlipidemia  49.31 0.800 <.0001 0.797 <.0001 
 Inflammatory 
bowel disorder  
10.21 0.758 <.0001 0.761 <.0001 
 Liver disease  1.32 0.648 <.0001 0.648 <.0001 
 Malignancies  9.35 0.770 <.0001 0.772 <.0001 
 Parkinson’s  3.48 0.698 <.0001 0.692 <.0001 
 Psychotic illness  5.57 0.741 <.0001 0.736 <.0001 
 Renal disease  0.29 0.392 <.0001 0.394 <.0001 
 Rheumatoid 
arthritis  
13.98 1.083 0.0219 1.077 0.0329 
 Thyroid disorder  13.25 0.731 <.0001 0.728 <.0001 
 Transplant  0.25 0.897 0.5107 0.891 0.4858 
 Tuberculosis  0.27 0.678 0.0084 0.672 0.0073 
 Pain  42.89 0.665 <.0001 0.667 <.0001 
 Pain and 
inflammation  
25.49 0.903 <.0001 0.901 <.0001 
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Using the random-intercept model, the pharmacy-level variance component was 
estimated to be 0.03459 with a standard error of 0.004477. Testing the null hypothesis of no 
random effects and complete independence of all the observations using a likelihood ratio test 
based on residual pseudo likelihoods yielded a chi-square of 151.99 (p<0.0001), indicating non-
zero covariance parameters (or presence of random effect). The residual intraclass correlation 
coefficient (ρ) for the random intercept model was estimated to be 0.0104 which indicates that 
1.04% of the unexplained variation after controlling for patient-level variables could be 
attributed to variation between pharmacies.   
 Glaucoma  9.17 0.881 <.0001 0.881 <.0001 
Race 
 North American 
Native 
0.17 Reference Reference Reference Reference 
 Unknown race  0.04 1.964 0.8912 1.606 0.2728 
 White  60.10 3.541 <.0001 2.916 <.0001 
 Black  39.26 2.291 0.1868 1.907 0.0032 
 Other  0.20 2.623 0.1338 2.179 0.0048 
 Asian  0.17 1.675 0.2357 1.353 0.2883 
 Hispanic  0.05 2.197 0.8098 1.887 0.1010 
Sex 
 Female 65.29 Reference Reference Reference Reference 
 Male 34.71 0.996 0.8180 0.992 0.6472 
Age  70.81±11.49 1.011 <.0001 1.011 <.0001 
Cost share group
a 
 No Premium 
Subsidy 
44.35 Reference Reference Reference Reference 
 Subsidy group 1  2.94 1.121 0.1876 1.130 0.0959 
 Subsidy group 2 50.70 1.028 0.4040 1.035 0.0753 
 Subsidy group 3 2.01 1.049 0.9916 1.057 0.3507 
Prescriptions per month  5.14±3.01 1.452 <.0001 1.458 <.0001 
a
Subsidy Group 1 consisted of beneficiaries with 100% premium-subsidy and no copayment. Subsidy Group 2 
consisted of beneficiaries with 100% premium-subsidy and low copayment/high copayment and beneficiaries with a 
low income subsidy, a 100% premium-subsidy and high copayment. Subsidy Group 3 consisted of beneficiaries 
with low income subsidy, 15% copayment and 25%-100% premium-subsidy. 
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Table 9 shows the agreement between the unadjusted quality indicator scores and the 
risk-adjusted quality indicator scores. Low quality outliers are those pharmacies whose scores on 
the pharmacy quality indicator are significantly lower than the average quality score in this 
sample of pharmacies according to the 95% confidence interval of the measures. High quality 
outliers are those pharmacies whose pharmacy quality indicator scores are significantly higher 
than the average quality score in this sample of pharmacies according to the 95% confidence 
interval of the measures. Pharmacies of medium quality are those whose quality scores are not 
significantly different from the average quality score in the sample.  
Agreement between pharmacy classification based on unadjusted and risk-adjusted scores 
was least when risk adjustment was based on the shrinkage estimators of the random intercept 
model (κ=0.38). Similar levels of agreement was seen when risk adjustment was done using a 
random intercept model (κ=0.59) and a classical logistic regression model (κ=0.57). 
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Table 9. Agreement in identifying Pharmacy Quality Outliers: Comparison of unadjusted 
and risk-adjusted pharmacy quality indicator scores – ACEI/ARB 
Outlier 
status based 
on 
unadjusted  
performance 
rating 
Outlier Status Based on Risk Adjustment 
Method 1
a
 Method 2
b
 Method 3
c
 
 Low Medium High Low Medium High Low Medium High 
Low  98 61 1 106 53 1 44 115 1 
Medium  30 298 26 32 299 23 6 342 6 
High  2 54 112 2 54 112 1 97 70 
Percentage 
change in 
classification 
(%)
d
  
26.7 27.8 19.4 24.3 26.3 17.6 13.7 38.3 9.09 
Overall κe  0.57 0.59 0.38 
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Percentage change was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the initial classification. 
e
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
 
Table 10 shows a comparison of the three different risk adjustment methods used. 
Pharmacy classification based on risk-adjusted scores obtained using Method 1 and 2 showed 
nearly perfect agreement (κ=0.97). Classification based on Method 3 showed less than moderate 
agreement with classification based on Method 1 (κ=0.56) and Method 2 (κ=0.55). Method 3 
also identified fewer high and low quality outliers compared to the other risk adjustment 
methods.  
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Table 10. Agreement in identifying Pharmacy Quality Outliers: Comparison of risk 
adjustment methods – ACEI/ARB 
Outlier status 
Based on Risk 
Adjustment 
Method 
Outlier Status Based on Risk Adjustment Method 
Method 1
a
 Method 2
b
 
Method 2
b
   
Low Medium High 
Low  130 10 0 
Medium  0 403 3 
High  0 0 136 
Overall κd  0.97 
Method 3
c
     
Low Medium High Low Medium High 
Low  51 0 0 51 0 0 
Medium  79 413 62 89 406 59 
High  0 0 77 0 0 77 
Overall κd  0.56  0.55  
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based 
on the risk adjustment method with higher values indicating greater agreement 
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Sulphonylurea 
At the patient-level, PDC measures for this class of medications were computed for 
13,280 Medicare patients who met eligibility criteria. These patients were attributed to a total of 
275 pharmacies in the state for which quality indicator scores were computed according to 
NCQA specifications. 
Table 11 shows the odds ratio estimates of patient characteristics used to predict 
adherence to sulphonylurea medications using a classical logistic regression model and a 
random-intercept model. The odds ratio estimates of all patient characteristics were similar in 
both models. Adherence was strongly associated with the average number of prescriptions per 
month. Patients with a greater number of average prescriptions per month had higher odds of 
being adherent to sulphonylurea medications. Presence of most medical conditions, as measured 
by the RxRisk measure, was associated with significantly lesser odds of being adherent to 
medications. The c-statistic was 0.702 for the classical logistic regression model and 0.7124 for 
the random intercept model which shows good discriminative ability for both models. 
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Table 11. Odds ratio estimates of baseline patient characteristics in risk adjustment models 
- Sulfonylurea 
Baseline Characteristics 
Prevalence(%) 
or 
Classical Logistic 
Regression Model 
Random Intercept 
Model 
Mean ± SD Point 
Estimate 
P-Value 
Point 
Estimate 
P-Value 
RxRisk Category  
 Anxiety and 
tension  
11.18 0.689 <.0001 0.686 <.0001 
 Asthma  17.42 0.736 <.0001 0.736 <.0001 
 Bipolar disorder  0.27 1.438 0.3690 1.408 0.3974 
 Cardiac disease  9.12 0.685 <.0001 0.687 <.0001 
 Vascular disease  9.50 0.866 0.0500 0.861 0.0420 
 Cystic fibrosis  0.09 1.268 0.7195 1.326 0.6699 
 Depression  26.05 0.670 <.0001 0.666 <.0001 
 Hypertension 92.87 0.702 <.0001 0.700 <.0001 
 Epilepsy  16.58 0.711 <.0001 0.711 <.0001 
 ESRD  0.23 0.804 0.5974 0.816 0.6229 
 Gastric acid 
disorder  
31.40 0.651 <.0001 0.652 <.0001 
 Gout  8.17 0.855 0.0349 0.854 0.0347 
 AIDS  2.09 0.810 0.1163 0.801 0.0985 
 Hyperlipidemia 54.89 0.787 <.0001 0.789 <.0001 
 Inflammatory 
bowel disorder  
11.31 0.794 0.0002 0.796 0.0003 
 Liver disease  1.39 0.971 0.8689 0.966 0.8443 
 Malignancies  9.19 0.880 0.0671 0.883 0.0762 
 Parkinson’s  3.95 0.895 0.3036 0.891 0.2857 
 Psychotic illness  6.62 0.761 0.0017 0.759 0.0016 
 Renal disease  0.29 0.679 0.2743 0.676 0.2715 
 Rheumatoid 
arthritis  
11.08 1.028 0.7572 1.028 0.7589 
 Thyroid disorder  12.27 0.878 0.0424 0.876 0.0413 
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Using the random-intercept model, the pharmacy-level variance component was 
estimated to be 0.03888 with a standard error of 0.01235. Testing the null hypothesis of no 
random effects and complete independence of all the observations using a likelihood ratio test 
 Transplant  0.20 0.572 0.1911 0.587 0.2123 
 Tuberculosis  0.34 0.656 0.2106 0.658 0.2164 
 Pain  43.33 0.690 <.0001 0.690 <.0001 
 Pain and 
inflammation  
26.47 0.895 0.0152 0.893 0.0138 
 Glaucoma  10.93 0.843 0.0077 0.840 0.0066 
Race 
 North American 
Native 
0.66 Reference Reference Reference Reference 
 Unknown race  0.05 0.534 0.2158 0.511 0.4182 
 White  49.79 2.315 0.0018 2.191 0.0069 
 Black  49.18 1.734 0.0968 1.643 0.0848 
 Other  0.19 1.862 0.3389 1.822 0.2515 
 Asian  0.07 1.191 0.9372 1.127 0.8734 
 Hispanic  0.06 1.003 0.7357 1.001 0.9987 
Sex 
 Female 63.01 Reference Reference Reference Reference 
 Male 36.99 1.009 0.8391 1.015 0.7325 
Age  70.16±11.06 1.014 <.0001 1.014 <.0001 
Cost share group
a 
 No Premium 
Subsidy 
37.04 Reference Reference Reference Reference 
 Subsidy group 1  3.81 0.870 0.4594 0.872 0.3730 
 Subsidy group 2 56.75 0.825 0.0119 0.829 <.0001 
 Subsidy group 3 2.39 1.094 0.1561 1.103 0.4771 
Prescriptions per month  5.99±3.10 1.371 <.0001 1.374 <.0001 
a
Subsidy Group 1 consisted of beneficiaries with 100% premium-subsidy and no copayment. Subsidy Group 2 
consisted of beneficiaries with 100% premium-subsidy and low copayment/high copayment and beneficiaries with a 
low income subsidy, a 100% premium-subsidy and high copayment. Subsidy Group 3 consisted of beneficiaries with 
low income subsidy, 15% copayment and 25%-100% premium-subsidy. 
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based on residual pseudo likelihoods yielded a chi-square of 15.83 (p<0.0001), indicating non-
zero covariance parameters (or presence of random effect). The residual intraclass correlation 
coefficient (ρ) for the random intercept model was estimated to be 0.01168 which indicates that 
1.17% of the unexplained variation after controlling for patient-level variables could be 
attributed to variation between pharmacies.   
Table 12 shows the agreement between the unadjusted quality indicator scores and the 
risk-adjusted quality indicator scores. Low quality outliers are those pharmacies whose scores on 
the pharmacy quality indicator are significantly lower than the average quality score in this 
sample of pharmacies according to the 95% confidence interval of the measures. High quality 
outliers are those pharmacies whose pharmacy quality indicator scores are significantly higher 
than the average quality score in this sample of pharmacies according to the 95% confidence 
interval of the measures. Pharmacies of medium quality are those whose quality scores are not 
significantly different from the average quality score in the sample.  
Agreement between pharmacy classification based on unadjusted and risk-adjusted scores 
was the same (κ=0.61) when risk adjustment was done using a classical logistic regression model 
and a random intercept model and much lesser when risk adjustment was done using the 
shrinkage estimators of the random intercept model (κ=0.29). 
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Table 12. Agreement in identifying Pharmacy Quality Outliers: Comparison of 
unadjusted and risk-adjusted pharmacy quality indicator scores - Sulfonylurea 
Outlier 
status based 
on 
unadjusted  
performance 
rating 
Outlier Status Based on Risk Adjustment Method 
Method 1
a
 Method 2
b
 Method 3
c
 
 Low Medium High Low Medium High Low Medium High 
Low  40 16 0 40 16 0 12 44 0 
Medium  8 134 14 8 134 14 0 156 0 
High  2 21 40 2 21 40 0 47 16 
Percentage 
change in 
classification 
(%)
d
  
20 21.6 25.9 20 21.6 25.9 0 36.8 0 
Overall κe  0.61 0.61 0.29 
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Percentage change was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the initial classification. 
e
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based 
on the risk adjustment method with higher values indicating greater agreement 
 
Table 13 shows a comparison of the three different risk adjustment methods used. 
Pharmacy classification based on risk-adjusted scores obtained using Method 1 and 2 showed 
perfect agreement (κ=1). Classification based on Method 3 showed less than moderate agreement 
with classification based on Method 1 and Method 2 (κ=0.35). Method 3 also identified fewer 
high and low quality outliers compared to the other risk adjustment methods.  
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Table 13. Agreement in identifying Pharmacy Quality Outliers: Comparison of risk 
adjustment methods - Sulfonylurea 
Outlier status 
Based on Risk 
Adjustment 
Method 
Outlier Status Based on Risk Adjustment Method 
Method 1
a
 Method 2
b
 
Method 2
b
   
Low Medium High 
Low  50 0 0 
Medium  0 171 0 
High  0 0 54 
Overall κd  1 
Method 3
c
     
Low Medium High Low Medium High 
Low  12 0 0 12 0 0 
Medium  38 171 38 38 171 38 
High  0 0 16 0 0 16 
Overall κd  0.35  0.35  
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based 
on the risk adjustment method with higher values indicating greater agreement 
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Biguanides 
At the patient-level, PDC measures for this class of medications were computed for 
15,468 Medicare patients who met eligibility criteria. These patients were attributed to a total of 
311 pharmacies in the state for which quality indicator scores were computed according to 
NCQA specifications. 
Table 14 shows the odds ratio estimates of patient characteristics used to predict 
adherence to biguanides using a classical logistic regression model and a random-intercept 
model. The odds ratio estimates of all patient characteristics were similar in both models. 
Adherence was strongly associated with the average number of prescriptions per month. Patients 
with a greater number of average prescriptions per month had higher odds of being adherent to 
biguanide medications. Beneficiaries in subsidy group 2 i.e., beneficiaries with 100% premium-
subsidy and low copayment/high copayment and those with a low income subsidy, a 100% 
premium-subsidy and high copayment were less likely to be adherent when compared to 
beneficiaries with no premium subsidy or cost sharing with an estimated odds ratio of 0.856 
(using classical logistic regression model) and 0.857 (using the random intercept model). 
Presence of most medical conditions, as measured by the RxRisk measure, was associated with 
significantly lesser odds of being adherent to medications. The c-statistic was 0.723 for the 
classical logistic regression model and 0.73 for the random intercept model which shows good 
discriminative ability for both models. 
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Table 14. Odds ratio estimates of baseline patient characteristics in risk adjustment models 
- Biguanides 
Baseline Characteristics  
Prevalence(%) 
or 
Classical Logistic 
Regression Model 
Random Intercept 
Model 
Mean ± SD Point 
Estimate 
P-Value 
Point 
Estimate 
P-Value 
RxRisk Category  
 Anxiety and 
tension  
11.26 0.670 <.0001 0.671 <.0001 
 Asthma  17.35 0.747 <.0001 0.749 <.0001 
 Bipolar disorder  0.41 1.171 0.5989 1.159 0.6251 
 Cardiac disease  7.27 0.570 <.0001 0.572 <.0001 
 Vascular disease  8.02 0.780 0.0004 0.779 0.0004 
 Cystic fibrosis  0.08 0.189 0.0158 0.193 0.0176 
 Depression  28.63 0.662 <.0001 0.662 <.0001 
 Hypertension 91.80 0.683 <.0001 0.683 <.0001 
 Epilepsy  17.71 0.697 <.0001 0.701 <.0001 
 ESRD  0.08 2.161 0.2575 2.282 0.2272 
 Gastric acid 
disorder  
32.00 0.705 <.0001 0.703 <.0001 
 Gout  6.24 0.680 <.0001 0.679 <.0001 
 AIDS  2.04 0.923 0.5300 0.928 0.5544 
 Hyperlipidemia 59.57 0.818 <.0001 0.817 <.0001 
 Inflammatory 
bowel disorder  
10.86 0.767 <.0001 0.769 <.0001 
 Liver disease  1.08 0.744 0.0944 0.743 0.0946 
 Malignancies  8.74 0.767 <.0001 0.770 <.0001 
 Parkinson’s  4.34 0.860 0.1081 0.857 0.1006 
 Psychotic illness  7.29 0.890 0.1349 0.887 0.1265 
 Renal disease  0.25 0.472 0.0332 0.476 0.0357 
 Rheumatoid 
arthritis  
10.69 0.910 0.2567 0.906 0.2369 
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Using the random-intercept model, the pharmacy-level variance component was 
estimated to be 0.02726 with a standard error of 0.01020. Testing the null hypothesis of no 
random effects and complete independence of all the observations using a likelihood ratio test 
 Thyroid disorder  12.28 0.783 <.0001 0.781 <.0001 
 Transplant  0.18 0.604 0.2195 0.618 0.2413 
 Tuberculosis  0.25 0.995 0.9895 1.021 0.9552 
 Pain  43.53 0.614 <.0001 0.614 <.0001 
 Pain and 
inflammation  
27.99 0.833 <.0001 0.831 <.0001 
 Glaucoma  9.84 0.927 0.2155 0.923 0.1953 
Race 
 North American 
Native 
0.41 Reference Reference Reference Reference 
 Unknown race  0.03 1.593 0.8995 1.448 0.7043 
 White  53.01 2.572 0.0408 2.373 0.0061 
 Black  46.11 1.566 0.5194 1.446 0.2386 
 Other  0.22 2.273 0.4933 2.114 0.1297 
 Asian  0.12 3.079 0.2419 2.853 0.0853 
 Hispanic  0.10 1.179 0.4108 1.096 0.8839 
Sex 
 Female 63.91 Reference Reference Reference Reference 
 Male 36.09 1.047 0.2498 1.049 0.2279 
Age  67.94±10.98 1.012 <.0001 1.012 <.0001 
Cost share group
a 
 No Premium 
Subsidy 
38.65 
Reference Reference Reference Reference 
 Subsidy group 1  2.82 1.207 0.1434 1.220 0.2211 
 Subsidy group 2 56.32 0.856 0.0011 0.857 0.0003 
 Subsidy group 3 2.21 1.031 0.8820 1.032 0.7997 
Prescriptions per month  5.86±3.08 1.404 <.0001 1.405 <.0001 
a
Subsidy Group 1 consisted of beneficiaries with 100% premium-subsidy and no copayment. Subsidy Group 2 
consisted of beneficiaries with 100% premium-subsidy and low copayment/high copayment and beneficiaries with a 
low income subsidy, a 100% premium-subsidy and high copayment. Subsidy Group 3 consisted of beneficiaries with 
low income subsidy, 15% copayment and 25%-100% premium-subsidy. 
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based on residual pseudo likelihoods yielded a chi-square of 10.34 (p=0.0013), indicating non-
zero covariance parameters (or presence of random effect). The residual intraclass correlation 
coefficient (ρ) for the random intercept model was estimated to be 0.00821 which indicates that 
0.82% of the unexplained variation after controlling for patient-level variables could be 
attributed to variation between pharmacies.  Table 15 shows the agreement between the 
unadjusted quality indicator scores and the risk-adjusted quality indicator scores. Low quality 
outliers are those pharmacies whose scores on the pharmacy quality indicator are significantly 
lower than the average quality score in this sample of pharmacies according to the 95% 
confidence interval of the measures. High quality outliers are those pharmacies whose pharmacy 
quality indicator scores are significantly higher than the average quality score in this sample of 
pharmacies according to the 95% confidence interval of the measures. Pharmacies of medium 
quality are those whose quality scores are not significantly different from the average quality 
score in the sample.  
Agreement between pharmacy classification based on unadjusted and risk-adjusted scores 
was similar when risk adjustment was done using a random intercept model (κ=0.54) and a 
classical logistic regression model (κ=0.53) and the least when risk adjustment was done using 
the shrinkage estimators of the random intercept model (κ=0.19). 
 
 
 
 
52 
   
 
Table 15. Agreement in identifying Pharmacy Quality Outliers: Comparison of 
unadjusted and risk-adjusted pharmacy quality indicator scores - Biguanides 
Outlier 
status based 
on 
unadjusted  
performance 
rating 
Outlier Status Based on Risk Adjustment 
Method 1
a
 Method 2
b
 Method 3
c
 
 Low Medium High Low Medium High Low Medium High 
Low  36 26 0 36 26 0 8 54 0 
Medium  17 156 17 17 156 17 0 189 1 
High  1 17 41 1 16 42 0 49 10 
Percentage 
change in 
classification 
(%)
d
  
33.3 21.6 29.3 33.3 21.2 28.8 0 35.3 0.09 
Overall κe  0.53 0.54 0.19 
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Percentage change was calculated for each risk adjustment method using the classification based on the risk 
adjustment method as the initial classification. 
e
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based 
on the risk adjustment method with higher values indicating greater agreement 
 
Table 16 shows a comparison of the three different risk adjustment methods used. 
Pharmacy classification based on risk-adjusted scores obtained using Method 1 and 2 showed 
nearly perfect agreement (κ=0.99). Classification based on Method 3 showed less than moderate 
agreement with classification based on Method 1 (κ=0.23) and Method 2 (κ=0.23). Method 3 
also identified fewer high and low quality outliers compared to the other risk adjustment 
methods.  
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Table 16. Agreement in identifying Pharmacy Quality Outliers: Comparison of risk 
adjustment methods - Biguanides 
Outlier status 
Based on Risk 
Adjustment 
Method 
Outlier Status Based on Risk Adjustment Method 
Method 1
a
 Method 2
b
 
Method 2
b
   
Low Medium High 
Low  54 0 0 
Medium  0 198 0 
High  0 1 58 
Overall κd  0.99 
Method 3
c
     
Low Medium High Low Medium High 
Low  8 0 0 8 0 0 
Medium  46 199 47 46 198 48 
High  0 0 11 0 0 11 
Overall κd  0.23  0.23  
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based 
on the risk adjustment method with higher values indicating greater agreement 
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Thiazolidinediones 
At the patient-level, PDC measures for this class of medications were computed for 3,955 
Medicare patients who met eligibility criteria. These patients were attributed to a total of 92 
pharmacies in the state for which quality indicator scores were computed according to NCQA 
specifications. 
Table 17 shows the odds ratio estimates of patient characteristics used to predict 
adherence to thiazolidinediones (TZDs) using a classical logistic regression model. A random 
intercept model could not be specified due to sample size restrictions. Adherence was strongly 
associated with the average number of prescriptions per month. Patients with a greater number of 
average prescriptions per month had higher odds of being adherent to TZDs. Beneficiaries in 
subsidy group 1, i.e., beneficiaries with 100% premium-subsidy and no copayment and those in 
subsidy group 2, i.e., beneficiaries with 100% premium-subsidy and low copayment/high 
copayment and those with a low income subsidy, a 100% premium-subsidy and high copayment 
were significantly more likely to be adherent when compared to beneficiaries with no premium 
subsidy or cost sharing with an estimated odds ratio of 2.575 and 2.055 for subsidy groups 1 and 
2 respectively. Presence of most medical conditions, as measured by the RxRisk measure, was 
associated with significantly lesser odds of being adherent to medications. The c-statistic was 
0.727 which shows good discriminative ability for the classical logistic regression model. 
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Table 17. Odds ratio estimates of baseline patient characteristics in risk adjustment models 
- Thiazolidinediones 
Baseline Characteristics 
Prevalence (%) or Classical Logistic Regression 
Model 
Mean ± SD Point Estimate P-Value 
RxRisk Category 
 Anxiety and tension  11.88 0.606 <.0001 
 Asthma  17.72 0.788 0.0706 
 Bipolar disorder  0.2 1.254 0.7666 
 Cardiac disease  7.36 0.535 <.0001 
 Vascular disease  8.42 0.647 0.0012 
 Cystic fibrosis  0.03 <0.001 0.9677 
 Depression  28.39 0.685 <.0001 
 Hypertension 92.47 0.520 <.0001 
 Epilepsy  18.1 0.797 0.0212 
 ESRD  0.63 0.584 0.2632 
 Gastric acid disorder  34.97 0.694 <.0001 
 Gout  7.0 0.743 0.0342 
 AIDS  1.87 0.661 0.1143 
 Hyperlipidemia 59.62 0.792 0.0016 
 Inflammatory bowel disorder  12.19 0.751 0.0096 
 Liver disease  1.95 1.074 0.7839 
 Malignancies  8.80 0.820 0.1279 
 Parkinson’s  4.12 0.745 0.1301 
 Psychotic illness  7.79 0.755 0.0598 
 Renal disease  0.46 0.773 0.6191 
 Rheumatoid arthritis  10.49 1.131 0.4471 
 Thyroid disorder  10.87 0.843 0.1458 
 Transplant  0.10 0.739 0.7642 
 Tuberculosis  0.53 0.910 0.8471 
 Pain  47.05 0.630 <.0001 
 Pain and inflammation  27.84 0.741 0.0002 
 Glaucoma  13.0 0.715 0.0015 
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Table 18 shows the agreement between the unadjusted quality indicator scores and the 
risk-adjusted quality indicator scores. Low quality outliers are those pharmacies whose scores on 
the pharmacy quality indicator are significantly lower than the average quality score in this 
sample of pharmacies according to the 95% confidence interval of the measures. High quality 
outliers are those pharmacies whose pharmacy quality indicator scores are significantly higher 
than the average quality score in this sample of pharmacies according to the 95% confidence 
interval of the measures. Pharmacies of medium quality are those whose quality scores are not 
significantly different from the average quality score in the sample. 
 
 
 
Race 
 Unknown race 1.49 Reference Reference 
 White 39.9 2.480 0.0448 
 Black 58.3 1.769 0.6331 
 Other 0.18 1.475 0.8973 
Sex 
 Female 65.66 Reference Reference 
 Male 34.34 1.218 0.0114 
Age  68.76±11.48 1.013 0.0001 
 No Premium Subsidy 25.99 Reference Reference 
 Subsidy group 1  7.16 2.575 0.0018 
 Subsidy group 2 65.56 2.055 0.0095 
 Subsidy group 3 1.29 1.239 0.2611 
Prescriptions per month  6.18±3.35 1.331 <.0001 
a
Subsidy Group 1 consisted of beneficiaries with 100% premium-subsidy and no copayment. Subsidy Group 2 
consisted of beneficiaries with 100% premium-subsidy and low copayment/high copayment and beneficiaries with a 
low income subsidy, a 100% premium-subsidy and high copayment. Subsidy Group 3 consisted of beneficiaries 
with low income subsidy, 15% copayment and 25%-100% premium-subsidy. 
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Table 18. Agreement in identifying Pharmacy Quality Outliers: Comparison of unadjusted and 
risk-adjusted pharmacy quality indicator scores 
Outlier status 
based on 
unadjusted  
performance 
rating 
Outlier Status Based on Risk Adjustment 
Using Classical Logistic Regression 
 Low Medium High 
Low  19 3 0 
Medium  1 40 5 
High  1 5 18 
Percentage change 
in classification 
(%)
d
  
9.5 16.7 21.7 
Overall κe  0.74 
d
Percentage change in classification was calculated for each risk adjustment method using the 
classification based on the risk adjustment method as the initial classification. 
e
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and 
ratings based on the risk adjustment method with higher values indicating greater agreement 
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Statins 
At the patient-level, PDC measures for this class of medications were computed for 
60,913 Medicare patients who met eligibility criteria. These patients were attributed to a total of 
644 pharmacies in the state for which quality indicator scores were computed according to 
NCQA specifications. 
Table 19 shows the odds ratio estimates of patient characteristics used to predict 
adherence to statins using a classical logistic regression model and a random-intercept model. 
The odds ratio estimates of all patient characteristics were similar in both models. Adherence 
was strongly associated with the average number of prescriptions per month. Patients with a 
greater number of average prescriptions per month had higher odds of being adherent to statins. 
Presence of most medical conditions, as measured by the RxRisk measure, was associated with 
significantly lesser odds of being adherent statins. Beneficiaries with no copayment and 100% 
premium subsidy were more likely to be adherent when compared to beneficiaries with no 
premium subsidy or cost sharing with an estimated odds ratio of 1.99 (using classical logistic 
regression model) and 2.08 (using the random intercept model). The c-statistic was 0.723 for the 
classical logistic regression model and 0.7316 for the random intercept model which shows good 
discriminative ability for both models. 
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Table 19. Odds ratio estimates of baseline patient characteristics in risk adjustment models 
- Statins 
Baseline Characteristics 
Prevalence(%) 
or 
Classical Logistic 
Regression Model 
Random Intercept Model 
Mean±SD Point 
Estimate 
P-Value 
Point 
Estimate 
P-Value 
RxRisk Category  
 Anxiety and 
tension  
11.72 0.674 <.0001 0.672 <.0001 
 Asthma  20.15 0.644 <.0001 0.645 <.0001 
 Bipolar disorder  0.29 0.804 0.2129 0.803 0.2115 
 Cardiac disease  8.05 0.618 <.0001 0.616 <.0001 
 Vascular disease  9.84 0.841 <.0001 0.833 <.0001 
 Cystic fibrosis  0.06 0.467 0.0358 0.445 0.0248 
 Depression  28.84 0.658 <.0001 0.657 <.0001 
 Diabetes  36.24 0.635 <.0001 0.629 <.0001 
 Hypertension 89.72 0.642 <.0001 0.639 <.0001 
 Epilepsy  15.17 0.696 <.0001 0.691 <.0001 
 ESRD  0.18 1.299 0.2549 1.289 0.2702 
 Gastric acid 
disorder  
34.04 0.654 <.0001 0.651 <.0001 
 Gout  6.04 0.693 <.0001 0.691 <.0001 
 AIDS  2.44 0.973 0.6443 0.969 0.5917 
 Inflammatory 
bowel disorder  
9.98 0.748 <.0001 0.750 <.0001 
 Liver disease  1.28 0.673 <.0001 0.679 <.0001 
 Malignancies  8.91 0.732 <.0001 0.734 <.0001 
 Parkinson’s  3.75 0.711 <.0001 0.709 <.0001 
 Psychotic illness  5.73 0.920 0.0610 0.914 0.0443 
 Renal disease  0.27 0.820 0.2588 0.827 0.2832 
 Rheumatoid 
arthritis  
13.60 1.069 0.1003 1.069 0.1015 
 Thyroid disorder  14.87 0.794 <.0001 0.792 <.0001 
 Transplant  0.20 0.673 0.0516 0.664 0.0449 
 Tuberculosis  0.28 0.771 0.1327 0.767 0.1268 
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Using the random-intercept model, the pharmacy-level variance component was 
estimated to be 0.03972 with a standard error of 0.005499. Testing the null hypothesis of no 
random effects and complete independence of all the observations using a likelihood ratio test 
based on residual pseudo likelihoods yielded a chi-square of 123.85 (p<0.0001), indicating non-
zero covariance parameters (or presence of random effect). The residual intraclass correlation 
coefficient (ρ) for the random intercept model was estimated to be 0.01193 which indicates that 
 Pain  42.18 0.649 <.0001 0.653 <.0001 
 Pain and 
inflammation  
25.08 0.813 <.0001 0.811 <.0001 
 Glaucoma  8.86 0.851 <.0001 0.846 <.0001 
Race 
 North American 
Native 
0.12 Reference Reference Reference Reference 
 Unknown race  0.05 1.527 0.8305 1.465 0.4451 
 White  65.32 2.562 <.0001 2.450 0.0021 
 Black  34.06 1.602 0.7737 1.540 0.1373 
 Other  0.21 2.294 0.0849 2.206 0.0243 
 Asian  0.19 1.600 0.8811 1.519 0.2423 
 Hispanic 0.05 1.431 0.6758 1.303 0.5809 
Sex 
 Female 63.49 Reference Reference Reference Reference 
 Male 36.51 1.151 <.0001 1.151 <.0001 
Age  70.33±10.59 1.014 <.0001 1.014 <.0001 
Cost share group
a 
 No Premium 
Subsidy 
46.15 Reference Reference Reference Reference 
 Subsidy group 1  2.41 1.990 <.0001 2.080 <.0001 
 Subsidy group 2 49.41 1.248 0.3423 1.263 <.0001 
 Subsidy group 3 2.03 1.093 0.0025 1.108 0.1194 
Prescriptions per month  5.49±3.10 1.464 <.0001 1.474 <.0001 
a
Subsidy Group 1 consisted of beneficiaries with 100% premium-subsidy and no copayment. Subsidy Group 2 
consisted of beneficiaries with 100% premium-subsidy and low copayment/high copayment and beneficiaries with a 
low income subsidy, a 100% premium-subsidy and high copayment. Subsidy Group 3 consisted of beneficiaries with 
low income subsidy, 15% copayment and 25%-100% premium-subsidy. 
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1.19% of the unexplained variation after controlling for patient-level variables could be 
attributed to variation between pharmacies.  Table 20 shows the agreement between the 
unadjusted quality indicator scores and the risk-adjusted quality indicator scores. Low quality 
outliers are those pharmacies whose scores on the pharmacy quality indicator are significantly 
lower than the average quality score in this sample of pharmacies according to the 95% 
confidence interval of the measures. High quality outliers are those pharmacies whose pharmacy 
quality indicator scores are significantly higher than the average quality score in this sample of 
pharmacies according to the 95% confidence interval of the measures. Pharmacies of medium 
quality are those whose quality scores are not significantly different from the average quality 
score in the sample. 
Agreement between pharmacy classification based on unadjusted and risk-adjusted scores 
was similar when risk adjustment was done using a random intercept model (κ=0.50) and a 
classical logistic regression model (κ=0.49) and the least when risk adjustment was done using 
the shrinkage estimators of the random intercept model (κ=0.35). 
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Table 20. Agreement in identifying Pharmacy Quality Outliers: Comparison of 
unadjusted and risk-adjusted pharmacy quality indicator scores - Statins 
Outlier 
status based 
on 
unadjusted  
performance 
rating 
Outlier Status Based on Risk Adjustment 
Method 1
a
 Method 2
b
 Method 3
c
 
 Low Medium High Low Medium High Low Medium High 
Low  81 56 1 81 56 1 37 101 0 
Medium  51 295 30 51 297 28 5 360 11 
High  2 43 85 3 43 84 1 81 48 
Percentage 
change in 
classification 
(%)
d
  
39.5 25.1 26.7 40 25 25.7 13.9 33.6 18.6 
Overall κe  0.49 0.50 0.35 
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Percentage change in classification was calculated for each risk adjustment method using the classification based 
on the risk adjustment method as the initial classification. 
e
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based 
on the risk adjustment method with higher values indicating greater agreement 
 
Table 21 shows a comparison of the three different risk adjustment methods used. 
Pharmacy classification based on risk-adjusted scores obtained using Method 1 and 2 showed 
nearly perfect agreement (κ=0.98). Classification based on Method 3 showed less than moderate 
agreement with classification based on Method 1 (κ=0.49) and Method 2 (κ=0.50). Method 3 
also identified fewer high and low quality outliers compared to the other risk adjustment 
methods.  
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Table 21. Agreement in identifying Pharmacy Quality Outliers: Comparison of risk 
adjustment methods - Statins 
Outlier status 
Based on Risk 
Adjustment 
Method 
Outlier Status Based on Risk Adjustment Method 
Method 1
a
 Method 2
b
 
Method 2
b
   
Low Medium High 
Low  133 2 0 
Medium  1 392 3 
High  0 0 113 
Overall κd  0.98 
Method 3
c
     
Low Medium High Low Medium High 
Low  43 0 0 43 0 0 
Medium  91 394 57 92 396 54 
High  0 0 59 0 0 59 
Overall κd  0.49  0.50  
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based 
on the risk adjustment method with higher values indicating greater agreement 
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Identifying High Quality Outliers - Top 20%  
Agreement of unadjusted and risk-adjusted pharmacy quality indicator scores in 
identifying the best pharmacies as defined by the top 20% of all pharmacies was examined for 
each measure. The results are presented in Table 22. Cohen’s Kappa between pharmacy 
classification based on unadjusted and risk-adjusted quality indicator scores ranged from 0.47-
0.63. Kappa values were similar for the three types of risk adjustment methods used indicating 
that there was not much difference in the level of agreement between pharmacy classification 
based on risk-adjusted and unadjusted scores when different risk adjustments were used. False 
positive error rates, calculated as the proportion of pharmacies identified as being in the top 20% 
by the unadjusted scores and not by the risk-adjusted scores ranged from 7.46%-11%. False 
negative error rates, calculated as the proportion of pharmacies identified as being in the top 20% 
by the risk-adjusted scores and not by the unadjusted scores was much higher and ranged from 
29%-42%.  
We also examined agreement between the different risk adjustment methods used in the 
identification of the top 20% of the distribution. The results are given in the Table 23. Almost 
perfect agreement was observed between pharmacy classification based on Method 1 (using 
classical logistic regression) and Method 2 (using a random intercept model) with Kappa values 
ranging from 0.97-1.00. Pharmacy rankings based on Method 3 (using shrinkage estimators of 
random-intercept model) were in strong agreement with rankings based on Method 1 and 
Method 2 (0.79<κ<0.86).    
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Table 22. Summary of agreement between unadjusted and risk-adjusted pharmacy quality 
indicator scores in identifying high quality outliers as those pharmacies in top 20% of the 
distribution 
Performanc
e measure 
Risk Adjustment Method 
Method 1
a
 Method 2
b
 Method 3
c
 
κd False 
positiv
e (%)
e 
False 
negative
(%)
e 
κd False 
positive
(%)
e
 
False 
negative
(%)
e 
κd False 
positiv
e(%)e
e
 
False 
negative
(%)
e 
Beta 
blockers
 
0.61 7.86 30.6 0.61 7.86 30.6 0.63 7.46 29.03 
CCBs
 
0.52 9.71 38.5 0.52 9.71 38.5 0.53 9.5 37.7 
ACE 
I/ARBs
 
0.56 8.8 34.8 0.57 8.64 34.1 0.56 8.8 34.8 
Sulfonylurea
 
0.60 8.18 30.9 0.60 8.18 30.9 0.58 8.64 32.7 
Biguanides
 
0.60 8.06 31.75 0.60 8.06 31.8 0.62 7.66 30.2 
TZDs
 
0.47 11 42.1 - - - - - - 
Statins
 
0.57 8.54 34.1 0.57 8.54 34.1 0.58 8.35 33.3 
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
e
False positive and false negative error rates were calculated for each risk adjustment method assuming the 
classification based on the risk adjustment method to be the correct classification 
 
Table 23. Summary of agreement between unadjusted and risk-adjusted pharmacy quality 
indicator scores in identifying high quality outliers as those pharmacies in top 20% of the 
distribution 
Performance 
measure 
Risk Adjustment Method 
Method 1
a
 - Method 2
b
 Method 1
a
 – Method 3c Method 2b - Method 3c  
Cohen’s Kappa κd Cohen’s Kappa κd Cohen’s Kappa κd 
Beta blockers
 
0.97 0.82 0.81 
CCBs
 
1 0.79 0.79 
ACE I/ARBs
 
0.99 0.81 0.81 
Sulfonylureas
 
1 0.86 0.86 
Biguanides
 
1 0.84 0.84 
Statins
 
0.98 0.85 0.85 
a
Based on classical logistic regression model 
b
Based on random-intercept model 
c
Based on shrinkage estimators of random-intercept model  
d
Overall Kappa coefficient is a measure of agreement between unadjusted performance ratings and ratings based on 
the risk adjustment method with higher values indicating greater agreement 
e
False positive and false negative error rates were calculated for each risk adjustment method assuming the 
classification based on the risk adjustment method to be the correct classification 
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CHAPTER V 
DISCUSSION & CONCLUSIONS 
With the United States healthcare system moving towards a value-driven model, the 
demand for evidence of value and quality has reached medication use systems. The Center for 
Medicare and Medicaid Services (CMS) has already started reporting quality at the drug-plan 
level thereby intensifying the need for pharmacy-level quality measures. PQA demonstration 
projects have successfully tested some quality measures, including the adherence-based 
measures used in this study that are bound to be implemented soon. As measurement of 
pharmacy performance becomes a reality, we are a step closer to having publicly available report 
cards and pay-for-performance initiatives for pharmacies. As such, it is imperative that pharmacy 
quality measures be adjusted for patient case mix so that they accurately reflect pharmacy 
performance and can be used to make fair comparisons with other pharmacies with a different 
case mix. This study presents and compares three approaches to address the issue of risk 
adjustment - the use of a classical logistic regression model, a random intercept model and the 
shrinkage estimators of the random intercept model.  
In order to be a valid risk adjustment method it is necessary that the patient 
characteristics adjusted for have an influence on the patient outcome used as a measure of 
facility quality of care. The classical and hierarchical logistic regression models used included 
the same measures of patient co-morbidity, socio-economic status and demographics as 
predictors of adherence.  The logistic regression model and the random intercept model 
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displayed good predictive ability (c-statistics>0.7) for all adherence measures thereby 
justifying the choice of patient characteristics to be adjusted for when measuring pharmacy 
quality. Also, it is worth mentioning here that accounting for a random effect of a pharmacy only 
slightly improved the discriminative ability of the model. The highest improvement in c-statistic 
was only 0.0104, seen in the regression models used to predict adherence to Sulpohnylurea 
medications. Further, the low intra-class correlation coefficients show that pharmacy-level 
variation does not explain much of the variation in adherence unexplained by patient 
characteristics. The residual intraclass correlation coefficient for the random intercept models 
ranged from 0.008 to 0.012 for the six adherence measures. These findings suggest that although 
pharmacy-level factors may have a significant impact, they may not be as important as patient-
level factors in determining adherence. This also served to reinforce our belief that the use of 
adherence-based measures which are not adjusted for patient-level factors will lead to unfair 
assessments of pharmacy quality. 
After risk adjusting pharmacy quality indicator scores by three different methods, we 
compared the pharmacy classification as low, medium or high quality outliers based on the 95% 
confidence intervals of unadjusted and risk-adjusted scores. It was seen that the classification of 
pharmacies as low or high quality outliers changed after quality scores were risk-adjusted. 
Higher levels of agreement was observed between pharmacy classification based on unadjusted 
scores and risk-adjusted scores obtained from the classical logistic regression model with 
Cohen’s Kappa values ranging from 0.5-0.74 and the percentage change in classification ranging 
from 16.3%-28.4%. Minimal agreement was seen between pharmacy rankings based on 
unadjusted scores and risk-adjusted scores obtained from the shrinkage estimators of the 
hierarchical model with Cohen’s Kappa values ranging from 0.19-0.35 and the percentage 
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change in classification ranging from 30.9%-37%. The lack of agreement between unadjusted 
and risk-adjusted rankings have been demonstrated for other quality measures. Li et al.
35
 studied 
the impact of different statistical methodologies in risk adjusting quality measures (QMs) of the 
Nursing Home quality report cards published by CMS. They reported an overall kappa of 0.59-
0.76 for the agreement between unadjusted and risk-adjusted measures in identifying quality 
outliers using the 95% confidence intervals of QMs.  
In our study, the pharmacy rankings based on the different risk adjustment methods 
showed moderate to high agreement with each other. These results suggest that the risk-adjusted 
measures, despite the statistical methodology used, provide a more robust and more useful 
assessment of pharmacies than the corresponding unadjusted measure. Rankings based on 
logistic regression models and random intercept models showed nearly perfect agreement in 
identifying statistical outliers. A similar finding was reported in another study comparing these 
two methods for the quality assessment of American College of Surgeons-National Surgical 
Quality Improvement Program (ACS-NSQIP) hospitals with regard to colorectal operation 
morbidity and mortality.
36 
This is not surprising given that the estimated coefficients for the 
covariates used in both models were similar. Although we did not find the outlier classification 
to vary much in our case, it would be advisable to use the more sophisticated and statistically 
rigorous approach of hierarchical modeling which accounts for the lack of independence in the 
data when measuring pharmacy quality for the purposes of pay-for-performance programs or 
generating quality report cards.  
There was only moderate agreement between rankings based on the first two risk 
adjustment methods which used O/E ratios and the third method which used exponentiation of 
the random intercept parameters of the hierarchical model as a measure of pharmacy 
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performance. It was observed that the third method classified fewer pharmacies as outliers. The 
random intercept parameters are equivalent to shrinkage estimators produced in an empirical 
Bayes estimation procedure. The shrinkage estimator works on the principle that the precision of 
the estimate of facility quality produced using the sample of patients served at that facility 
(unshrunk estimate) will depend upon the sample size and variance. As such, the shrinkage 
estimator is so designed that the performance of facilities with smaller sample sizes and higher 
variance within them would be shrunk to an estimate away from their unshrunk estimate and 
closer to the average performance in the entire population and vice-versa for facilities with a 
larger sample size. Thus, the shrinkage estimator is biased in nature and this method of risk 
adjustment often tends to produce fewer outliers. For this reason and its difficulty in 
interpretation, Mukammel et al. caution against the use of this method for producing risk-
adjusted measures to rank providers for quality report cards.
37
  
CMS currently rewards the top 20% of hospitals as a part of their Premier Hospital 
Quality Incentive Demonstration program.
38
 The top 10% receive an incentive of 2% and the 
next 10% receive an incentive of 1% bonus payment per Medicare patient along with their 
regular Medicare prospective payment.
38
 This structure is also used by CMS for a pay-for-
performance demonstration program for nursing homes.
35
 We examined the effect of case-mix 
adjustment of pharmacy quality measures on identification of pharmacies eligible for a reward if 
such a program were to be implemented for pharmacies serving the Medicare beneficiaries. 
There was moderate to substantial agreement between unadjusted and risk-adjusted pharmacy 
classification. However, when compared to risk-adjusted scores, unadjusted scores classified 8-
12% of the low performing pharmacies as high performing and classified 20-30% of the 
pharmacies in the top 20% as low performers. When we compared the three risk adjustment 
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methods in a pairwise manner, we observed almost perfect agreement between them in 
identifying high performing pharmacies. This suggests that the risk-adjusted measures would 
provide more robust quality information than the unadjusted measure. 
As shown here, not adequately addressing the effects of patient case mix while measuring 
quality could lead to misclassification of pharmacies. This could have severe implications for 
pharmacies if these measures are used for pay-for-performance programs or even generating 
quality report cards. For example, Mehta et al.
26
 found that adjusting for patient characteristics 
(including age, body mass index, race and type of insurance) and treatment opportunities 
affected hospital rankings and their classification in the CMS pay-for-performance categories 
based on a process measure for the treatment of acute myocardial infarction. Similar results were 
reported in studies examining the effect of risk adjustment on New York State and Massachusetts 
Cardiac Surgery Report cards
39,40
 and Nursing Home Compare report cards.
36,41
 All these studies 
demonstrate that unadjusted quality measures will reward facilities with the healthiest patient 
case mix rather than the best performers. Also, this would unjustly penalize facilities serving 
sicker patients, minority groups and the lower socio-economic strata. This would ultimately lead 
to healthcare facilities selecting healthier patients and refusing care for sicker patients in order to 
obtain a better performance rating. In fact, results from a study of the New York State Cardiac 
Surgery Report suggest that cardiologists may be “cream skimming” or avoiding the sickest 
patients because of their concern about their rankings.
42
 Preliminary results from another study 
about the Nursing Home Compare report cards also point towards the occurrence of cream 
skimming with at least some nursing homes reporting a change in the type of patients they admit 
following the publication of the report cards.
43
    
71 
   
An important limitation of this study and most studies on methods of case-mix 
adjustment of quality measures is that there are no true or real quality rankings that can be used 
to compare the performance of the risk adjustment methods. However, the results of this study 
show that regardless of the method used, risk-adjusted scores produce more robust indicators of 
pharmacy quality than unadjusted scores. It was also observed that the use of shrinkage 
estimators for computing quality score as a risk adjustment method tends to be biased and 
produce fewer outliers than the conventional methods of using the observed to expected (O/E) 
ratios. Thus, it may not be desirable to use this method for risk adjustment especially when the 
intended use of quality scores is to produce quality report cards tailored to the general public. In 
this study, the quality of pharmacies was evaluated individually for each of the seven medication 
adherence based measures. Future research should address the question of developing a 
composite measure of pharmacy performance for each patient that can then be risk-adjusted to 
arrive at one unique measure of quality for each pharmacy. The pharmacies rankings based on 
this measure can then be easily used to produce report cards or for pay-for-performance 
programs.
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RxRisk Chronic Disease Categories and associated Medication Class(es) 
Chronic Disease AHFS (American Hospital 
Formulary System) medication 
category 
AHFS Category 
Number 
Anxiety and tension Benzodiazepines, Miscellaneous 
anxiolytics, Sedative, and Hypnotics 
28:24:08, 28:24:92 
Asthma Sympathomimetic agents, Adrenals 12:12, 68:04, 86:16 
Bipolar disorder Antimanic agents 28:28 
Cardiac disease Cardiac drugs 24:04 
Coronary/peripheral vascular 
disease 
Anticoagulants, 
Hemorrheologic agents 
20:24, 20:12:04 
Cystic fibrosis Mucolytic agents, 
Digestants 
48:24, 56:16 
Depression Antidepressants 28:16:04 
Diabetes Antidiabetics 68:20 
Epilepsy Anticonvulsants 28:12 
End Stage Renal Disease Hematopoietic agents 20:16 
Gastric acid disorder Miscellaneous GI drugs 56:92, 56:28 
Glaucoma  52:40, 52:92 
Gout Unclassified therapeutic agents 92:16 
HIV Antivirals, Miscellaneous 
antiinfectives 
08:18, 08:92 
Hyperlipidemia Antilipemic agent 24:06 
Hypertension Hypotensive agent 24:08, 24:20, 24:24, 
24:28, 24:32, 40:28 
Inflammatory bowel disorder Sulfonamide 56:92, 08:12:20 
Liver disease Ammonia detoxicants 40:10 
Malignancies Antineoplastic agents, Hematopoietic 
antiemetics 
10:00, 56:22, 20:16 
Pain Nonsteroidal anti-inflammatory agents 28:08:08 
Pain and inflammation Opiates 28:08:04 
Parkinsons disease Antiparkinsonian agents 28:36 
Psychotic illness Tranquilizers 28:16:08 
Renal disease Potassium removing resins 40:18:18 
Rheumatoid arthritis Adrenals, Gold compounds, 
Antimalarial agents 
68:04, 60:00, 08:30:08 
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Thyroid disorder Thyroid agents, 
Antithyroid agents 
68:36 
Transplant Unclassified therapeutic agents 92:44 
Tuberculosis Antituberculosis agents 08:16:04 
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LIST OF MEDICATIONS 
Beta-Blocker Medications 
 acebutolol HCL 
 atenolol 
 betaxolol HCL 
 bisoprolol fumarate 
 carteolol HCL 
 carvedilol 
 labetalol HCL 
 metoprolol 
succinate 
 metoprolol tartrate 
 nadolol 
 nebivolol HCL 
 penbutolol sulfate 
 pindolol 
 propranolol HCL 
 timolol maleate 
BB Combination Products 
 atenolol & chlorthalidone 
 bisoprolol & HCTZ 
 nadolol & 
bendroflumethiazide 
 metoprolol & HCTZ 
 propranolol & HCTZ 
 timolol & HCTZ 
Note: Active ingredients are limited to oral formulations only.  Excludes the BB sotalol because it is indicated for the 
treatment of ventricular arrhythmias (and not for hypertension). 
 
 
 
Angiotensin-converting enzyme (ACE) inhibitor or Angiotensin-receptor blocker (ARB) 
ARB Medications 
 candesartan 
 eprosartan 
 irbesartan 
 losartan 
 olmesartan  
 telmisartan 
 valsartan 
ACE Inhibitor Medications 
 benazepril 
 captopril  
 enalapril 
 fosinopril  
 lisinopril 
 moexipril 
 perindopril 
 quinapril  
 ramipril  
 trandolopril  
ACE Inhibitor Combination Products 
 amlodipine & 
benazepril 
 benazepril & HCTZ  
 captopril & HCTZ  
 enalapril & HCTZ  
 enalapril & 
felodipine 
 fosinopril & HCTZ 
 lisinopril & HCTZ 
 moexipril & HCTZ 
 lisinopril & 
nutritional 
supplement 
 quinapril & HCTZ  
 trandolopril-
verapamil HCL 
ARB Combination Products 
 candesartan & 
HCTZ  
 eprosartan & HCTZ 
 telmisartan & 
amlodipine 
 irbesartan & HCTZ  
 losartan & HCTZ  
 amlodipine & 
olmesartan 
 olmesartan & HCTZ 
 telmisartan & 
HCTZ 
 aliskiren & 
valsartan 
 
 valsartan & HCTZ 
 amlodipine & 
valsartan 
 amlodipine  & 
valsartan & HCTZ 
Note: Active ingredients are limited to oral formulations only. 
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Calcium Channel Blockers 
CCB Medications 
 amlodipine besylate 
 diltiazem HCL 
 felodipine 
 isradipine 
 nicardipine HCL 
 nifedipine (long 
acting only) 
 verapamil HCL 
 nisoldipine  
CCB Combination Products 
 amlodipine besylate & 
benazepril HCL  
 amlodipine & valsartan 
 amlodipine & valsartan & 
HCTZ 
 enalapril maleate & 
felodipine 
 telmisartan & amlodipine 
 amlodipine & olmesartan 
 trandolopril & verapamil 
HCL 
 amlodipine & atorvastatin 
Note: Active ingredients are limited to oral formulations only.  Excludes CCB nimodipine since it has a limited indication 
for use following a subarachnoid hemorrhage. 
 
Biguanide Medications 
Biguanides 
 metformin  
Biguanide & Sulfonylurea Combination Products 
 glipizide & metformin  glyburide & 
metformin 
Biguanide & Thiazolinedione Combination 
Products 
 rosiglitazone & metformin  pioglitazone & 
metformin 
Biguanide & Meglitinide Combinations 
 repaglinide & metformin 
Biguanide & DPP-IV Inhibitor Combinations 
 sitagliptin & metformin 
Note: Active ingredients are limited to oral formulations only 
(includes all dosage forms). 
 
Sulfonylureas 
Sulfonylureas 
 acetohexamide 
 chlorpropamide  
 glimepiride 
 glipizide  
 glyburide 
 tolazamide 
 tolbutamide 
Sulfonylurea & Biguanide Combination Products 
 glipizide & 
metformin 
 glyburide & metformin 
Sulfonylurea & Thiazolidinedione Combination 
Products 
 rosiglitazone & 
glimepiride 
 pioglitazone & glimepiride 
Note: Active ingredients are limited to oral formulations only 
(includes all salts and dosage forms). 
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Thiazolidinediones 
Thiazolidinediones 
 pioglitazone  rosiglitazone  
Thiazolinedione & Biguanide Combination 
Products 
 rosiglitazone & metformin  pioglitazone & 
metformin 
Thiazolidinedione & Sulfonylurea Combination 
Products 
 rosiglitazone & glimepiride  pioglitazone & 
glimepiride 
Note: Active ingredients are limited to oral formulations only 
(includes all dosage forms). 
 
Statin Medications 
Statins 
 lovastatin 
 rosuvastatin  
 fluvastatin 
 atorvastatin 
 pravastatin  simvastatin 
 
Statin Combination Products 
 niacin & lovastatin 
 atorvastatin & 
amlodipine 
 niacin & 
simvastatin 
 pravastatin & 
aspirin 
 ezetimibe & 
simvastatin 
Note: The active ingredients are limited to oral formulations only (includes all dosage forms). 
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